 
Providing Brain Control of Extracorporeal Devices to 
Patients With Quadriplegia  
Protocol Number: HS -12-00476 
National Clinical Trial (NCT) Identified Number :  [STUDY_ID_REMOVED]  
Principal Investigator:  Richard Andersen  
IDE Sponsor: NA  
Funded by: NIH  
Version Number:  v.1  
15 April  2012 
 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  1 PROTOCOL NUMBER:  DARPA: 16384  
 
 
TITLE:  Revolutionizing Prosthetics  
 
 
STUDY PHASE:  Early feasibility   
 
 
STUDY ARMS:  Single (longitudinal)  
 
 
IND OR IDE #:    G120096  
 
 
PRINCIPAL INVESTIGATOR(S):    Richard Andersen, Ph.D.  
   Division of Biology 
   Mail Code 216- 76 
   California Institute of Technology  
   Pasadena, CA 91125  
   Telepone: (626) 395- 8336  
   Fax: (626) 795- 2397  
 
 
CO-INVESTIGATOR(S):  Charles Liu, M.D., Ph.D. 
   1520 San Pablo St  
   Suite 3800 
 Los Angeles, CA 90033 
 
 Christi Heck , M.D., Ph.D., M.M.M. 
   1520 San Pablo St  
 HCT 3000  
   Los Angeles, CA 90033 
 
 Mindy Aisen, M.D.  
 Rancho Los Amigos National Rehabilitation Center  
 7601 East Imperial Highway  
 Downey, CA 90242  
 
 
SPONSOR:    Richard Andersen, Ph.D.  
   Division of Biology 
   Mail Code 216- 76 
   California Institute of Technology  
   Pasadena, CA 91125  
   Telepone: (626) 395- 8336  
 Fax: (626) 795- 2397  
 
 
PARTICIPANTS/LOCATON S: California  Institute of Technology  (Caltech)  
 Keck Hospital of USC  (Keck Hospital)  
 Rancho Los Amigos National Rehab Center  (RLANRC) 
 
 
AMENDMENTS/REVISIONS:  None.  
 
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  2 Table of Contents  
 
Study Synopsis  ........................................................................................................................................................................ 5 
1.0 Background and Hypothesis  ..................................................................................................................................... 6 
1.1 Clinical Target  ......................................................................................................................................................... 6 
1.2 Study Overview  ....................................................................................................................................................... 6 
1.3 Background and Review  ......................................................................................................................................... 6 
1.3.1  Chronic Implantation of NeuroPort Arrays in Humans  .................................................................................. 6 
1.3.2  Posterior Parietal Cortex .................................................................................................................................  7 
1.3.3  Adverse Information  ....................................................................................................................................... 8 
1.3.4  Summary of Background Material  ................................................................................................................. 8 
1.4 Risk Analysis  .......................................................................................................................................................... 8 
1.4.1  Risks Associated with Related Clinical Procedures  ....................................................................................... 9 
1.4.2  Risks Identified for this Study  ........................................................................................................................ 9 
1.4.3  Justification for Study  .................................................................................................................................. 12 
1.5 Central Hypotheses  ............................................................................................................................................... 13 
2.0 Objectives and Purpose  ........................................................................................................................................... 14 
2.1 Primary Safety Objective  ...................................................................................................................................... 14 
2.2 Primary Effectiveness Objective  ........................................................................................................................... 14 
3.0 Study Design  ............................................................................................................................................................ 15 
3.1 Overview  ............................................................................................................................................................... 15 
3.2 Recruitment  ........................................................................................................................................................... 17 
3.3 Informed Consent  .................................................................................................................................................. 17 
3.4 Eligibility  .............................................................................................................................................................. 17 
3.5 Baseline/Pre -Implant  ............................................................................................................................................. 17 
3.6 Implantation  .......................................................................................................................................................... 17 
3.7 Healing Period  ....................................................................................................................................................... 18 
3.8 Study Period  .......................................................................................................................................................... 19 
3.8.1  Task 1  – Discrete Selection  .......................................................................................................................... 19 
3.8.2  Task 2 –  Continuous Positioning  .................................................................................................................. 19 
3.9 Explantation  .......................................................................................................................................................... 20 
3.10 Follow -up Care  ................................................................................................................................................. 21 
4.0 Device Information  .................................................................................................................................................. 22 
4.1 Device Overview  ................................................................................................................................................... 22 
4.2 IDE Number  .......................................................................................................................................................... 22 
4.3 NeuroPort Array  .................................................................................................................................................... 22 
5.0 Selection and Withdrawal of Subjects  ................................................................................................................... 24 
5.1 Inclusion Criteria  ................................................................................................................................................... 24 
5.2 Exclusion Criteria  ................................................................................................................................................. 24 
5.3 Withdrawal Criteria  ............................................................................................................................................... 25 
6.0 Stratification/Descriptive Factors/Randomization Scheme ................................................................................. 27 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  3 7.0 Study Agent Administration or Intervention and Toxicity Management Plan  .................................................. 28 
7.1 Device Administration  .......................................................................................................................................... 28 
7.2 Intervention Plan  ................................................................................................................................................... 28 
7.3 Toxicity Mangement Plan  ..................................................................................................................................... 28 
8.0 Assessment of Effectiveness and safety  .................................................................................................................. 29 
8.1 Side Effects Monitoring  ........................................................................................................................................ 29 
8.1.1  Side Effects Monitored During Study  .......................................................................................................... 29 
8.1.2  Side Effects Monitored After Study  ............................................................................................................. 29 
8.2 Adverse Event Reporting  ...................................................................................................................................... 29 
8.2.1  Adverse Event Definitions  ........................................................................................................................... 29 
8.2.2  Eliciting Adverse Event Information  ............................................................................................................ 30 
8.2.3  Recording and Assessing Adverse Events  .................................................................................................... 30 
8.2.4  Abnormal Test Findings  ............................................................................................................................... 30 
8.2.5  Causality and Severity Assessment  .............................................................................................................. 30 
8.2.6  Reporting of Adverse Events to the FDA  ..................................................................................................... 30 
8.2.7  Reporting of Adverse Events to the Responsible IRB  .................................................................................. 31 
8.2.8  List of Adverse Events  .................................................................................................................................  31 
8.2.9  Withdrawal of Subjects Due to Adverse Events  ........................................................................................... 33 
8.3 Data Monitoring Committee  .................................................................................................................................  33 
9.0 Clinical and Laboratory Evaluations and Clinical Calendar  .............................................................................. 34 
10.0 Criteria for Evaluation and Endpoint Definitions  ................................................................................................ 35 
11.0 Special Instructions  ................................................................................................................................................. 38 
12.0 Data Collection and Monitoring ............................................................................................................................. 39 
12.1 Case Report Forms  ........................................................................................................................................... 39 
12.2 Source Documentation and Timeliness of CRF Completion  ............................................................................ 39 
12.3 Retention of Study Record  ................................................................................................................................ 39 
12.4 Data Management  ............................................................................................................................................. 39 
12.5 Data Monitoring  ................................................................................................................................................ 39 
13.0 Statistical Considerations ........................................................................................................................................ 40 
13.1 Study Objectives  ............................................................................................................................................... 40 
13.2 Accrual  .............................................................................................................................................................. 40 
13.3 Study Design  ..................................................................................................................................................... 40 
13.4 Statistical Power of the Study  ........................................................................................................................... 40 
13.5 Power to Address Objectives  ............................................................................................................................ 40 
14.0 Registration Guideline  ............................................................................................................................................ 41 
14.1 Patient Registration  ........................................................................................................................................... 41 
14.2 Registration Forms and Records  ....................................................................................................................... 41 
15.0 Biohazard Containment  .......................................................................................................................................... 42 
16.0 Ethical and Regulatory Considerations  ................................................................................................................. 43 
17.0 References  ................................................................................................................................................................ 44 
APPENDICES  ....................................................................................................................................................................... 51 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  4  
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  5 Study Synopsis  
 
Brain signals may be used to control extracorporeal devices such as robotic effectors, prosthetic limbs, or computer 
systems.  For paralyzed patients, a device which implements such a possibility could represent an important step forward in 
providing some independence and the ability to interact with the environment.  This prospective, longitudinal, single -arm 
feasibility study will be used to evaluate the safety and effectiveness of the Neural Prosthetic System (NPS ), a device 
designed to record brain signals from the cortex, to control physical and virtual effectors.  The NPS uses electrodes which 
are already approved by the FDA for implantations of less than 30 days; an Investigational Device Exemption has been 
obtained from the FDA which allows implantation of 53 weeks in two subjects.  While the NeuroPort Array has been used 
in other longitudinal clinical studies with similar applications, the primary advantage and differentiating feature of our 
study is that we w ill use the posterior parietal cortex to extract cognitive brain signals representing intention and planning  
of reaching and grasping . This study is not intended to provide immediate treatment or benefits to its participants.  
However, the long -term implic ations of the study objectives could enable new technologies to provide assistance to people 
suffering from paralysis.  
 
NPS Feasibility Study  
Test Device  Neural Prosthetic System, consisting of two NeuroPort Arrays (Blackrock Microsystems, Salt Lake 
City,  UT) 
Cohort  People with high cervical spinal lesion (i.e., C4 or above)  
Primary Objectives  To assess the safety and evaluate the effectiveness of the NPS as a method for paralyzed people to 
interact with their environment.  
Device 
Configuration  The NPS consists of two NeuroPort Arrays.  Each NeuroPort Array consists of an electrode array 
(100 electrodes in a 10 x 10 configuration with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D); a 
titanium percutaneous connector, 19 mm diameter at the base.  
Study Design  A longitudinal clinical feasibility study.  Subjects participate in study sessions 3 -5 times per week at 
RLANRC (their place of normal clinical care) during the study period.  Each subject participates for 
a total of 66 weeks, including surgeries and foll ow-up care; the study period is 53 weeks.  
Number of Subjects 
to be Enrolled  Two subjects will be enrolled.  
Number of sites  One site, with multiple supporting institutions.  
Key Inclusion 
Criteria  Paralysis (high cervical spinal lesion, C4 or above) initi ated at least one year prior and stable for at 
least 3 months prior.  
Key Exclusion 
Criteria  Active psychiatric or medical illness which precludes surgery, stable participation in study sessions, 
or which requires MRI or other contraindicated procedure during time enrolled.  
Primary Efficacy 
Objective, 
Analysis, and 
Methods  The primary effectiveness objective is to evaluate the long -term effectiveness of the NPS.  The 
primary outcome variable is the accuracy with which tasks are performed during study sessions, 
which will be compared to the level of chance.  The secondary outcome variable is scoring on the 
Action Research Arm Test, a standard test used in occupational therapy to measure upper extremity 
limb function following cortical damage.  The tertiar y outcome variable is the quality -of-life index, 
measured before and after the study.  
Primary Safety 
Objective, 
Analysis, and 
Methods  The primary safety objective is to evaluate the safety of the NPS.  The primary outcome variable is 
the presence of infection or irritation around the implant site.  The secondary outcome variable is the 
Severe Adverse Event (SAE) rate measured per subject as a percentage of implant -days.  These 
factors will be measured during clinical follow -up care using standard observati ons and exams.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  6 1.0 Background and Hypothesis  
 
1.1 Clinical Target  
 
The number of patients suffering from some form of paralysis in the United States alone has been estimated to be 
from 1.7 million (U.S. Dept. Health Human Serv. 1995) to 5.6 million (Christopher & Dana Reeve Found. 2009). 
Paralysis can result from spinal cord lesion and other traumatic accidents, peripheral neuropathies, amyotrophic 
lateral sclerosis, multiple sclerosis, and stroke. Another 1.4 million patients have motor disabilities  due to limb 
amputation (U.S. Dept. Health Human Serv. 1995). A majority of these patients still have sufficiently intact cortex 
to plan movements, but they are unable to execute them. Thus they are candidates for assistance using cortical 
neural prostheti cs. 
 
Many studies have extracted motor execution signals from motor cortex in nonhuman primates and decoded them 
to predict and/or effect desired movements of a physical or virtual effector. In these studies, it was often observed 
that the monkeys quickly learned that they did not need to actually move their limb to bring a cursor or device 
under brain control. We refer to this as cognitive control, in which brain signals not directly related to executing a 
movement can nonetheless be harnessed for the task.  This control can be derived from motor imagery, planning, 
attention, decision making, or executive control, to name just a few of the cognitive signals that are potentially 
useful for neural prosthetics. The distinction is not the brain location of the recording but rather the type of signal 
that is being extracted. Cognitive neural prosthetics tap into brain signals that are neither motor execution 
commands nor sensory signals, but rather represent higher brain functions such as intention, multi -effecto r and 
sequential movement planning, attention, decision making, executive control, emotions, learning, and speech. 
Scientific understanding of the functional organization of cortex helps to guide the placement of electrodes and the 
choices of decoding algo rithms.  
 
Once decoded, neural signals can be used to control extracorporeal devices such as robotic effectors, prosthetic 
limbs, or computer systems.  Recently, the BrainGate study demonstrated cortical control of a computer cursor in 
human subject tests w ith severely paralyzed individuals. This milestone study marked a significant advance in the 
feasibility of neuromotor prostheses.  However, the results obtained in that study (now in a second phase of 
clinical trials, called BrainGate2) decoded motor execution signals, which is slower than decoding movement 
goals and other high -level cognitive movement processes.  
 
1.2 Study Overview  
 
The proposed study is investigator -initiated and led by Dr. Richard Andersen at Caltech. The device being tested is 
the Neural P rosthetic System (NPS), which consists of two microelectrode arrays (NeuroPort Array, Blackrock 
Microsystems, Salt Lake City, UT) to be implanted in the brain and two sets of recording electronics (NeuroPort 
Biopotential Signal Processors, Blackrock Micros ystems, Salt Lake City, UT) to amplify and record the neural 
signals. One microelectrode array will be implanted in Brodmann’s area 5 (BA5), and the other will be implanted 
in the anterior intraparietal (AIP) area. The NeuroPort Arrays, which are currently  FDA -approved for 
implantations of less than 30 days, will be implanted for a period of 53 weeks. Two subjects will be enrolled into 
the study.  The NPS will be used to allow study participants to control virtual and real world objects using 
imagined movem ents of their arms and hands. While the NeuroPort Array has been used in other longitudinal 
clinical studies with similar applications, the primary advantage and differentiating feature of our study is that we 
will use the posterior parietal cortex to extr act cognitive brain signals representing reach intention and planning. 
Therefore, the novelty in our study is twofold: (1) implantation for longer than 30 days, and (2) implantation into 
the posterior parietal cortex.  
 
1.3 Background and Review  
 
1.3.1 Chronic Implantation of NeuroPort Arrays in Humans  
 
The NeuroPort Array is currently under 510(k) clearance by the FDA for human implantations to record and 
monitor neural activity for less than 30 days.  The device has been cleared under IDE status to be chronically 
implanted in humans as part of the BrainGate and BrainGate2 clinical studies ( 1-8).  The first subject (S1) of the 
Braingate clinical trial was implanted in June 2004, after three years of paralysis, with a NeuroPort Array located 
in the M1 arm area, with no reported incidence of adverse events during surgery or post -operative care ( 2, 8).  A 
second subject (S2) was implanted in which electrical contacts had to be repaired, which caused a delay of 7 
months before recording could begin, and was a possible cause for signal loss at month 11 ( 2).  In both subjects, 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  7 multiple units were recorded (S1: 26.9 ± 14.2 units; S2: 53.2 ± 6.3 units) over several months well after the 30- day 
post-implantation mark (2).  Over the course of nine months after implantation, S1 learned to use neural activity to 
perform a variety of daily tasks such as opening email and operating a television ( 2, 8).  A third subject (S3), 
enrolled nine years af ter brainstem stroke, and a fourth subject (S4), enrolled six years after being diagnosed with 
amyotrophic lateral sclerosis (ALS), learned to use their neural activity to control a computer cursor over the 
course of 1003 days (S3), or 231 days (S4), after  implantation (3-8). 
 
In the BrainGate studies, NeuroPort Arrays have been implanted in the left precentral gyrus, in the M1 arm area 
knob.  It is well known from nonhuman primate work that neurons in this region process arm reaching trajectories 
(9, 10); however, an important result of the BrainGate studies is that despite paralysis in the subjects, this cortical 
area has continued to process movement trajectories.  Furthermore, in recent results documenting performance of 
online, closed -loop brain control 1000 days after implant, a subject achieved greater than 90% success rates while 
moving a cursor to targets on a screen ( 7).  These results suggest that neural interfaces can (i) operate successfully 
over years; and (ii) provide sufficient performance to interact with computers in meaningful ways ( 2, 6, 7). 
 
1.3.2 Posterior Parietal Cortex  
 
In both nonhuman primates and humans, pari etal cortex is traditionally thought to lie in the dorsal visual pathway 
encoding either spatial localization ( 11), or, alternatively, v isual guidance of action ( 12).  The posterior parietal 
cortex (PPC) is located between the occipital lobe (visual cortex) and postcentral gyrus (somatosensory cortex), 
and thus is naturally sit uated to process sensory inputs and project outputs to motor and pre -motor areas ( 13).  
Such high- level, multimodal processing of sensory inputs and motor outputs is one reason why we consider these 
signals as ideal candidates for cognitive control of neural interfaces: whereas motor cortex executes limb 
movement trajectories, the PPC processes plans which are then transferred to motor cortex for execution ( 14).  
Moreover, recent research suggests that PPC can provide a larger degree of useful prosthetic control signals as a 
result of its being situated at the interface between sensory and mot or systems.  
 
The posterior parietal cortex (PPC) is involved in transforming sensory inputs into plans for action –  so-called 
sensory -motor integration ( 15-17).  It is separated by the intraparietal sulcus into the superior parietal lobule and 
the inferior parietal lobule.  Within the intraparietal sulcus, subregions have been implicated in planning eye 
movements (la teral intraparietal area, LIP) ( 18), reach movements (parietal reach region, PRR, medial posterior 
bank of intraparietal sulcus comprising both medial intraparietal (MIP) and V6a areas) ( 19), and grasping (the 
lateral an terior intraparietal area, AIP) ( 20). Brodmann’s area 5 occupies the superior parietal lobule, and neurons 
within that area are active during sensory -motor integration and m otor planning for reaches ( 13, 21-24). In 
particular the dorsal aspect of area 5 (area 5d) has been implicated in reach planning ( 25).  The high- level, abstract 
nature of signals in these cortical areas is underscored by observations that plans can be formed and cancelled 
without execution ( 15, 26, 27), and that intended reach activity in PRR is coded in visual rather than limb 
coordinates (28).  In contrast, area 5d, which is believed to be positioned downstream of PRR, codes reaches 
largely i n limb coordinates ( 29, 30). PRR, AIP, and BA5 are particularly relevant to this application because 
reaching, grasping, and sensory integration for planning and guidance of these movements are integral components 
for the con trol of brain -machine interface effectors.  
 
Local field potentials (LFPs) are a continuous signal representing the sum of electrical activity in the brain tissue 
near an electrode.  We have shown that temporal structure in LFPs varies with planned or execu ted motor behavior 
(31), and found similar structure in LFPs recorded from LIP during saccade planning ( 32). Furthermore, we have 
shown that LFPs can support neural interface decodes as well as neuronal spiking ( 33-35), and in fact provide 
signals that are complementary to spikes. LFPs recorded from P PC encode behavioral state with fewer channels 
than spikes, whereas spikes provide direction of reach information with fewer channels than LFPs ( 31). Because 
LFPs are a summed signal, they may be less susceptible to degradation due to scarring ( 34, 36).  Furthermore, 
LFPs are more robust to array micro -motion (e.g., from sneezing), which can affect single unit sorting 
assignments.  Because of their stability, consistency, and potential for contributing to a neural interface, these 
signals may be a useful component of neural control.  
 
In human as in monkey, a number of PPC subregions have been identified which are activated for visually guided 
actions such as reaching and grasping. Some of these areas, based on cytoarchitectural, neuroimaging, and 
neuropsychological data, have been tentatively identi fied as homologues of well -studied nonhuman primate areas 
PRR, AIP, and BA5 ( 37-51). The activity of human PPC appears to retain desirable qualities of monkey PPC 
which make this cortical area an ideal candidate for cognitive neural prostheses  (40, 43).  Neuroimaging studies 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  8 with human subjects have demonstrated that activity within the posterior parietal cortex, including areas accessible 
by the NeuroPort Array along the intraparietal sulcus, can be used to decode reach and grasp activities ( 50). 
 
1.3.3 Adverse Information  
 
Implantation of the NeuroPort Array requires a craniotomy; blunt dissection of the a rachnoid space to separate the 
dura mater from the skull; incisions in the dura mater, and, finally, cortical insertion through the pia mater.  During 
insertion, electrodes penetrate the neural tissue and cause local edema in the brain tissue.  These featu res are 
common to many styles of electrodes which are designed to record the activity of single units from within the 
cortex, and so studies of other penetrating electrodes may be useful in understanding mechanisms in play when the 
NeuroPort Array is impla nted.  Acutely, local edema and hemorrhage are observed after implantation; these effects 
heal within weeks (52).  Over the first several months, the tissue response to intracortical electrodes is a comp act 
cellular sheath containing astrocytes and microglia ( 53).  Persistent inflammatory reaction may be responsible for 
a reduced density of neurons in the region of tissue near the electrode ( 52-54).  This phenomenon is not unique to 
microelectrodes for recording neural activity; it also occurs around the shank of electrodes used for deep brain 
stimulation (55).  The foreign body response has been implicated as one factor in a reduction of recording 
performance ov er time for neural implants ( 52).  This scarring tissue may contribute to varying degre es of 
electrical isolation of implanted electrodes from tissue, reducing the sensitivity of the electrode to biopotential 
signals generated in the surrounding cortex.  One study using CerePort Arrays found a decline in the amplitude of 
action potential sig nals of 2.4% per month over as many  as 31.7 months in three animals ( 56).  These factors 
represent a challenge for neural interfaces and for this  study.  Importantly, despite these factors, it appears that 
neural interface control with chronic CerePort or NeuroPort Array imp lantations is still possible ( 7, 56).  None of 
the authors of these studies indicate whether their investigations were conducted under GLP.  
 
1.3.4 Summary of Background Material  
 
The large body of work describing the nature of PPC activity in both nonhuman primate and  humans during 
reaching and grasping leads to several conclusions regarding its value for brain -machine interfaces:  
 
• Decodes of goals are very fast, in the order of 100 ms, which provides more rapid goal acquisition than 
primary motor cortex ( 14).   
• Trajectories can be decoded with similar fidelity to M1 ( 57-59).   
• At least two sequential goals can be represented and this feature can augment decoding performance of 
sequential limb movements ( 60) 
• Goal and trajectory information when combined provide better decoding of trajectories than trajectory  
information alone ( 57). 
• The representation of bilateral arm  movements within a single hemisphere can provide bimanual control 
from a single implant ( 61, 62). 
• The anterior intraparietal area (AIP) represents grasp shape which may reduce the number of cells needed 
to decode grasping ( 63, 64). 
• PPC has stronger local field potential (LFP) signals than motor cortex ( 65) and LFPs  can provide robust 
information on behavioral.   
 
In short, cognitive signals in PPC which perform multimodal sensory- motor integration are ideal candidates for 
control signals in paralyzed patients ( 14, 34, 66, 67).  Moreover, PPC can provide not only the signals found in 
motor cortex, but also high -level cognitive motor control signals, particularly those related to the goals of 
movement.  One advantage of this multiplicity of signals is that a single implant can allow for a wider variety of 
control variables ther eby improving the range and effectiveness of prosthetic control.  
 
1.4 Risk Analysis  
 
This early feasibility study is intended to evaluate the safety and effectiveness of the NPS, and thus is not intended 
to immediately provide the full benefits of direct brain -control of a prosthetic device to the subjects. The most 
serious risks to the subjects include those associated with anesthesia, brain surgery, and infection around the 
percutaneous connector.  However, we believe the long -term benefits of the study outwe igh the risks to the 
subject.  This section will present an analysis of the risks to the subject associated with this study, specific plans to 
mitigate these risks, and benefits expected to be derived from this study.   
 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  9 This study will include two (2) sub jects (selection criteria outlined in Section 5.0 ).  It is expected that a caregiver 
will be available and involved in daily wound care and monitoring of the subje ct’s wellbeing.  
 
1.4.1 Risks Associated with Related Clinical Procedures  
 
Components of this study which generate the majority of risk to the subject include the implantation and 
explantation surgeries, and the percutaneous connector.  Given the early stage of clinical development for the 
device investigated in this study, it may be useful to examine other procedures and operations which include 
similar components.  For example, b one-anchored hearing aids (BAHAs) rely on a titanium fixture similar to the 
titaniu m percutaneous component (the percutaneous connector) used in this study; rates of infection for BAHA 
devices have been reported in the range of 1.0% to 5.0%, with other complications (<1%) including persistent 
pain, granulation tissue, and persistent blee ding (68-71).  Infections which occur as a result of neurosurgery are 
potentially severe, but have a low incidence rate of 1.7% to 2.6% in the United States ( 72-78).  Placement of 
foreign bodies (specifically, shunts), CSF leakage, age, and duration of surgery have all been implicated as being 
significantly associated with surgical site infections for craniotomies and other neurosurgeries ( 73-75, 77).  
Prophylactic antibiotics may play a role in mitigating the risk of infection ( 73).  Anticipated adverse events 
associated with implantation of leads for epilepsy localization procedures include hemorrhage (0.8% to 2.5% of 
patients), infection (1.8% to 9.1%) and permanent neurological complications such as hemiparesis, aphasia, 
apraxia, Gerstmann syndrome, and other sensory and motor deficits  (0.6% to 1.5%; transient deficits occur 
somewhat more frequently) .  Resection of epileptic tissue is associated  with hemorrhage (0.7%) and infection 
(1.0%) and neurological deficits (about 3.3%), such as language, visual field, and motor deficits.  Deep Brain 
Stimulation (DBS) systems are associated with hemorrhage (1.1% to 3.9%) , infection (1.7% to 4%) , and  
neurological deficits such as hemiparesis (about 1.1% to 16% of patients) ( 79-85).   
 
1.4.2 Risks Identified for this Study  
 
• Excessive bleeding, fainting or feeling lightheaded, hematoma, or infection may result from having blood 
drawn (approximately 20cc) for pre -surgical screening. The expected frequency of these complications is 
rare.  Blood will be drawn for pre -surgical screening in a clinical care environment, by fully trained 
phlebotomist, and with appropriate resources and equipment on hand to handle any complications which 
may arise during the procedure.  Th e site from which blood is drawn will be thoroughly disinfected prior 
to the procedure, and protected afterward with antibiotic cream and bandage.  
 
• Risk of temporary sensations of warmth or localized heating during the pre and post -surgical MRI s.  The 
expe cted frequency of these complications is rare.  MRI is generally accepted as a procedure which has 
no harmful effects on biologic tissue ( 86).  Most complications associated with MRI have occurred 
because proper procedures (e.g., screening for metal objects) were not followed.  MRIs will be obtained 
in a clinical care environment, by trained radiology technicians, and with appropriate resources and 
equipment on hand to provide immediate medical assistance for any discomfort or complications which 
may occur.  
 
• Risks due to anesthesia, including aspiration, coughing, gagging, muscle spasms in the voice box, 
laryngospasm, bronchospasm, hypertension, tachycardia, damage to teeth and lips, swelling in the larynx, 
sore throat, hoarseness, heart attack, stroke, awareness during anesthesia, as well as unanticipated allergic 
reaction, and possibly death.  The expected frequency of these complications is low.  Anesthesia will be 
performed by a trained and board -certified anesthesiologist in the controlled medical environment of the 
operating suite.  The subject’s vital signs will be closely monitored during the entire procedure to watch 
for signs of complications due to anesthesia. The appropriate equipment and personnel will be available 
in the operating room to r espond to any complications due to anesthesia.  
 
• Intracranial hemorrhage, subdural hematoma, or epidural hematoma could result in headache, seizures, 
stroke, temporary or permanent neurologic impairment such as weakness, sensory loss, or coma, change 
in consciousness, or death.  The expected frequency of these complications is low: reports of 
neurosurgeries for the treatment of epilepsy or implantation of deep brain stimulators suggest that the 
incidence of bleeding may be between 0.8% and 3.9% ( 79-85, 87-90).  The surgery wil l be performed by 
trained and board -certified neurosurgeons in a controlled medical environment.  Major blood vessels will 
be avoided when the NeuroPort Array is implanted.  The subject’s vital signs will be closely monitored 
during the entire procedures t o watch for signs of surgical complications.  The appropriate equipment and 
personnel will be available in the operating room to respond to any complications due to anesthesia.  The 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  10 surgery will be performed according to the surgical manual included in the  510(k) application for the 
NeuroPort Array.  During the first two days of post -operative recovery period at USC the patient will 
undergo a CT scan to ensure that there is no bleeding from the device implantation procedure.  The 
patients will be placed on Keppra 500 mg PO q12 hours for two weeks for routine seizure prophylaxis.  
 
• Cerebrospinal Fluid (CSF) leakage during the surgery could result in a dull or throbbing headache or need 
for additional surgery, and could be a factor for increased risk of infecti on.  The expected frequency of 
these complications is low.  Evidence from the literature suggests that CSF leakage occurs in a low 
percentage of neurosurgeries: in epilepsy -related procedures, for example, the incidence of CSF leakage 
has been reported fro m 0.1% to 1.4% ( 88, 89).  CSF l eakage has been implicated as a potential fact or for 
increased risk of infection ( 74). Subjects will be monitored closely intraoperatively and during post -
operative critical care and throughout the study to watch f or signs of CSF leakage.  The attending 
physician will medicate pain as determined medically necessary, and will determine the appropriate 
response if medication is insufficient.  
 
• Infection could occur after surgery, including meningitis (which has the pot ential to cause brain damage 
or hearing loss).  The expected frequency of these complications is low: the rate of infection in similar 
neurosurgeries suggests that the rate of infection in this study may fall between 1.7% and 9.1%, with 
most reports from t he last decade within the range 1.7% to 4%  ( 79-85, 87-90).  After the implantation 
surgery, the subject will receive critical care for a minimum of 1 -2 days in the hospital.  The patient will 
receive 24 hours of IV antibiotics post -op.  During this time, the subject will be closely monitored for any 
signs of sys temic infection and infection around the wound.  If any infection occurs, the subject will 
receive immediate, appropriate clinical treatment.   
 
• Short -term pain in the head or neck might occur after surgery. The expected frequency of these 
complications is  moderate.  The subject will likely experience discomfort in the head and neck due to the 
nature of the surgery.  This pain will be short -term, and should dissipate during the post -operative critical 
care period, or during the healing period.  The attendin g physician will review each subject’s condition 
individually to determine whether the discomfort requires pharmacological intervention or other 
response.  
 
• Allergic reaction to the implanted devices is possible. The expected frequency of this complication is low.  
The NeuroPort Arrays are manufactured using biologically -safe materials, and have a documented history 
of being implanted both acutely and chronically without incidence of allergic reaction.  The NeuroPort 
Arrays are cleared under 510(k) approval for implantations of less than 30 days.  Subjects will be 
monitored closely during surgery, during the post -operative critical care period, and throughout the study 
to watch for signs of allergic reaction to the implanted device.  If symptoms occur, they w ill be evaluated 
by the attending physician, who will determine the proper response (ranging from medication to 
explantation and exit from the study).  
 
• Discomfort or lack of healing of the skin area could occur at or around the site of the implanted 
percut aneous connector.  The expected frequency of occurrence for this complication is moderate.  In 
studies of bone -anchored hearing aids, severe skin irritation or infection has been reported in 1.0% to 
5.0% of all observations ( 68-70). However, low -to-moderate skin irritation or infection (i.e., treatable v ia 
medication) has a higher rate of incidence –  5.1% to 14.0% (68, 71).  The wound site will be carefully 
monitored at all stages of the study, and the subject questioned, to detect signs of  discomfort or 
inadequate healing.  Such symptoms and conditions will be treated appropriately and immediately at the 
direction of the attending physician.  
 
• Tissue damage and histological responses could lead to functional deficits and increased long -term risk of 
neurological disorder.  The expected frequency of these complications is low.  When subdural electrode 
strips are placed to localize epileptogenic tissue, transient neurological deficits have been reported in 
5.6% to 11.1% of cases ( 87, 89). For tissue resection, rates of transient neurologic deficit increase to 8. 6% 
to 30% ( 90, 91).  Permanent neurologic deficits due to stereotactic electrode placement are rare, reported 
at 0.6% to 1.5% ( 85, 87, 91).  The NeuroPort Arrays are small (4 mm x 4 mm) and short (electrodes are 
1.5 mm in length), and will displace or damage small amounts of tissue.  During the study, the subject 
will be monitored on a daily basis by caregivers, and evaluated regularly by physicians, to watc h for 
seizures, loss of function, change in function or behavior, or any other signs of complications.  If any 
appearing symptoms are specified as exit criteria, the patient will be explanted and exit the study.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  11 Otherwise, the attending physician will jud ge whether conditions are serious enough to warrant 
explantation.  
 
• Chronic risk of infection associated with the implanted device. The expected frequency of this 
complication is low.  In studies of bone -anchored hearing aids, severe skin irritation or infe ction has been 
reported in 1.0% to 5.0% of all observations ( 68-70). However, low -to-moderate skin irritation or 
infection (i.e., treatable via medication) has a higher rate of incidence –  5.1% to 14.0% ( 68, 71).  Wound 
care will be performed regularly and will be monitored on a daily basis by the caregiver, and evaluated 
regularly by a physician. Excess redness, swelling, drainage, inflammation, or bleeding will be reported 
to the physician for appropriate urgent follow up care. If the subject experiences any allergic reaction to 
wound cleaning materials, appropriate substitutes will be found. During the course of the study any 
infections deemed minor or superficial in nature by the attending physicia n will be treated and monitored.  
An infection deemed serious in nature by the attending physician is a withdrawal criterion for the study 
(Section 4.2.4) and would result in immediate explantation and treatment of the infection.  
 
• The subject will be condu cting tasks involving electrical and/or mechanical equipment which could harm 
the subject.  The expected frequency of this complication is low.  End effectors, whether physical or 
virtual, will be electrically and mechanically isolated from the patient so that no physical or electrical 
harm to the subject could result from use of the effector.  The NeuroPort Biopotential Signal Processor 
receives data from the NeuroPort Array via an optically isolated amplifier.  Thus, electrical phenomena 
have no path from  an end effector, physical or virtual, back to the NeuroPort Array.  In the case of the 
physical effector, the physical device would be placed sufficiently distant from the subject so that no 
contact is possible during task behavior or otherwise. Additiona lly, an emergency stop button would be 
available to the operating technician which will immediately remove power from the physical effector.  
 
• The subject could experience frustration while trying to learn brain control in the study sessions.  The 
expected frequency of this complication is low.  We intend to select a subject who is mentally and 
emotionally able to participate despite the rigors of participation. Subject inclusion/exclusion criteria 
include: stable psychosocial support system, sufficient decision -making capacity, memory, and 
intellectual capabilities, and no evidence of psychotic illness or chronic psychiatric disorders. The subject 
will be monitored for signs of severe stress, fatigue, or frustration.  The difficulty and frequency of study 
tasks will be adjusted if any of these signs are observed.  
 
• Electrostatic discharge (ESD) from electrical contacts in the percutaneous pedestal connector presents 
a risk to the subject.   The expected frequency of this complication is low.  Electrode contacts  in the 
percutaneous connector are electrically isolated from other metal components of the percutaneous 
connector  and only ESD through the  electrode contacts constitutes a concern;  any discharges into the 
metal pedestal  will dissipate through the skin as normal.   The subject will be instructed to the leave the 
pedestal cap, which protects the electrical contacts, in place.   Only study investigators will be allowed to 
remove the cap for recording during study sessions. Study investigators will be trained in how to properly 
remove and replace the pedestal cap in order to avoid ESD.   The connector on the patient cable is 
designed to dissipate ESD during mating in order to reduce risks and minimize patient discomfort.  
 
• Headache and pain.  The expected frequency  of this complication is moderate.  Post- operative pain will 
be managed with pain medications and will be evaluated regularly during post -operative follow up with 
the physicians.  Additionally, the caregiver and study personnel will perform basic monitorin g on a more 
frequent basis and report any symptoms to physicians promptly for proper care.  
 
• Tissue response to the implanted device may cause a reduction in, or complete inability to, record neural 
signals. The expected frequency of this complication is mo derate.  The histological response of brain 
tissue to implanted electrodes is well studied and has been implicated in a reduction in the quality of 
neural signals recorded over time ( 52-56, 92).  However, the BrainGate and BrainGate clinical studies 
have demonstrated neural control using a NeuroPort Array after 1,000 days of implantation (7), and other 
nonclinical studies have demonstrated useful signals from chronic neural implants primates ( 56, 93-101).  
These results suggest that even with a reduction in signal quality, the NPS may still be viable as a neural 
interface.   
 
• The device may stop working on its own. Because the NPS is an electromechanical system, it is possible 
that some compone nt of the system may break and cause the device to stop working.  The device is 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  12 manufactured under a quality control system (Blackrock Microsystems), which reduces the chance of the 
device malfunctioning on its own.  Because the NPS comprises two NeuroPort  Arrays, if one breaks the 
other will still be able to provide neural signals.  In that situation, the functionality of the NPS may be 
reduced and the study tasks and outcomes will be adjusted accordingly, but still to address the safety and 
effectiveness of the device.  
 
1.4.3 Justification for Study  
 
The novelty of this study is that we intend to explore the safety and effectiveness of a long -term, cognitive neural 
implant.  This novelty is manifest in two primary aspects of the study: first, that we will implan t NeuroPort Arrays 
for a period of one year; and second, that we intend to use signals from posterior parietal cortex, which are 
involved in high -level plans for reaching and grasping. The nature of these signals is such that other benefits may 
be derived,  such as bimanual control, fast learning, fast adaptation, and dexterous manipulation of virtual or 
physical end effectors. We have structured this study to explore both the safety and the effectiveness of such a 
device.  
 
The primary risk to subjects in th is study is that of infection.  A reasonable expectation of the risk of chronic 
infection may be derived from the literature regarding bone -anchored hearing aids.  Similarly to the NPS, these 
devices use a bone- affixed titanium implant which remains expose d through the skin.  Rates of serious infection 
(i.e., requiring surgical intervention) associated with these similar devices range between 1.0% and 5.0%; rates of 
low or moderate infection (i.e., treatable extraoperatively) range from 5.1% to 14.0%.  Whil e the implants are not 
exactly the same (e.g., no osseointegration for the NPS), the materials and chronic, through -the-skin nature of the 
two implants suggests that similar rates of infection might apply to this percutaneous connectors in this study.  
With procedures in place to carefully monitor for signs of irritation and infection, it is our view that this risk is 
acceptable in the context of the benefits to be derived from the study.  
 
Other significant risks are associated with anesthesia and surgeries  to implant and explant the device. This section 
has presented data from the literature describing risks and complications from other, similar clinical procedures 
including deep brain stimulators, neurosurgical treatments for epilepsy, and general neurosur gical data.  For 
example, it is expected that rates of post -operative infection might fall in the range between 1.7% and 4.0%.  The 
subjects in this study will undergo surgery with a highly skilled clinical team, and will be carefully monitored 
post-operat ively with a standard 24 -hour course of antibiotics.  It is again our view that with proper management 
of the risk factors by an experienced team of physicians, the risks associated with anesthesia and surgery are 
acceptable in the context of the benefits of this study.  
 
The safety of the device has been demonstrated extensively in the literature.  Several instances of chronic 
implantations of NeuroPort Arrays exist in the literature for human subjects and CerePort Arrays for nonhuman 
primate subjects.  In one report from the BrainGate trials, performance of a brain -computer interface was 
evaluated 1000 days after implantation in a person with tetraplegia ( 7); other reports from that same clinical study 
have not described any clinical emergencies or trauma resulting from the implantation of the NeuroPort Array or 
participation in study tasks ( 1-6, 8).  Many studies exist which have evaluated data recorded with NeuroPort 
Arrays implanted in nonhuman primates ( 56, 93-101). These examples demonstrate a history of saf ety of the 
NeuroPort Array.  
 
The effectiveness of relying on signals from the posterior parietal cortex for neural interface control has also been 
well established in the literature. The posterior parietal cortex (PPC) forms a juncture between sensory and motor 
areas and is involved in sensory- motor integration ( 15-17).  A number of studies relying on electrophysiological, 
neuropsychological, and neuroimaging results have shown that in humans, areas BA5 and AIP are strongly 
activated during reaching and grasping ( 37-48).  Our lab group has been instrume ntal in advancing an 
understanding of the cognitive signals available in the posterior parietal cortex ( 14, 19, 27, 28, 31, 57, 58, 67, 102-
105). 
 
The proposed study will allow us to perform long- term brain -computer interface training, which takes advantage 
of neuroplasticity to enhance volitional con trol over neural activity. The information that is learned will provide a 
basis for the development of fully -implantable brain -computer interfaces that can control complex assistive 
technologies. Our main long -term goal, to utilize signals from chronic neu ral recordings to control external 
assistive devices, is likely to be perceived as a significant benefit by the targeted patient population. Individuals 
with high cervical spinal lesions consider restoration of hand and arm function to be a top priority fo r improving 
their ability to perform activities of daily living independently ( 106).  We believe that the potential benefits for the 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  13 targeted patient population, in concert with properly managed risk, amount to a strong justification for pursuing 
this clinical st udy. 
 
1.5 Central Hypotheses  
 
We hypothesize the following  regarding the safety of the device:  
 
(1) Implantation will not be associated with infection or irritation;  
(2) The Severe Adverse Event (SAE) rate, calculated as the number of SAEs per implant -day, will not rise above 
1% for any study subjects.  
 
We hypothesize the following regarding the effectiveness of the device:  
 
(1) Control over virtual and physical end effectors, as measured by accuracy, will be significantly greater than 
chance when using the NPS;  
(2) Action R esearch Arm Test (ARAT) scores will improve over the course of the trial when controlling virtual or 
physical end effectors  
(3) Using the NPS with either virtual or physical end effectors will result in significant increases in the subjects’ 
quality of life.  
 
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  14 2.0 Objectives and Purpose  
 
2.1 Primary Safety Objective  
 
The primary objective of this study is to evaluate the safety of the NPS.  The driving hypothes es are that the 
implantation will not be associated with infection or irritation , and that the SAE rate will  not rise above 1% .  These 
hypotheses  will be evaluated via the endpoints defined in Section 10.1.  
 
2.2 Primary Effectiveness Objective  
 
The primary effectiveness objective of this study is to evaluate the effectiveness of the NPS  in controlling virtual 
or physical end effectors .  The driving hypothes es are that control over the physical and virtual end effector s, as 
measured by accuracy, will be significantly greater than the level of chance ; that scores on the ARAT will improve 
over the course of the study; and, that using the NPS with either the virtual or physical end effector will result in 
significant increases in the participant’s quality of life.  These hypothes es will be evaluated via the endpoints 
defined in Section 10.2.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  15 3.0 Study Design  
 
3.1 Overview  
 
A prospective, longitudinal, single -arm early feasibility study will be u sed to examine the safety and effectiveness 
of using the NPS with physical and virtual end effectors. Figure 3 -1 illustrates the progression of a subject through 
the study from recruitment to study exit.  Two subjects will be enrolled, each implanted with the NPS for a period 
of 53 weeks.  The study is expected to take two years in total.    
 
At the end of the study period, it is expected that the subject will have the device removed, continue with follow -
up care, and end all study -related activities.  Howev er, it may be necessary to evaluate a continuation of the study 
period if the subject expresses a desire to keep the device.  The subject, caregiver, clinical team, and research 
support team will consult to determine whether it is safe and feasible to do s o.  If the subject and team agree to 
allow the device to remain implanted, a new informed consent for long- term follow up will be obtained, and the 
appropriate oversight bodies (i.e., FDA, IRB, and monitoring organization), will be notified.  
 
All surgical and medical care will be provided according to best medical practice, including protocol activities and 
care provided in an emergent situation.  
 
A schedule indicating the expected time required for each step of the study is listed in Table 3 -1. Because the 
Recruitment phase depends on the availability and qualifications of an as yet unknown person, there is no specific 
amount of time listed.  
 
Table 3 -1. Study time course  
Study Week  Study Phase  Section  
N/A Recruitment  3.2 
0 Informed Consent  3.3 
0 Eligibility  3.4 
1 Baseline/pre -implant  3.5 
2 Device implantation  3.6 
2 – 3 Healing period  3.7 
4 – 53 Study period  3.8 
54 Device explantation  3.8.3  
54 – 66 Follow -up care  4.0 
 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  16  
 
Figure 3 -1.  Participant progression through the proposed study.  
 

Doc: Proform   
 
Version date: 04/15/12  
Confidential  17 3.2 Recruitment  
 
The search for subjects will be conducted in collaboration with RLANRC .  Study applicants  will be invited to 
meet with the clinical investigators, during which the basic elements of the study will be presented and the 
applicant may ask questions.  If the applicant expresses interest in enrolling, then permission will be obtained from 
the applicant to view their medical records and speak with their primary care physician.  The inclusion criteria 
outlined in Section 5.1  will be evaluated according to the methods defined in Table 5 -1.  No tests will be 
performed on the applicant during recruitment.  All inclusion criteria will be evaluated via medical record review, 
consultation with the subject’s primary care physician, and interaction with the subject.  I f the applicant continues 
to express interest and meets all inclusion criteria to the satisfaction of the study investigators, the applicant may 
provide informed consent to join the study.  
 
3.3 Informed Consent  
 
Informed consent from study applicants will be obtained by Dr. Charles Liu, M.D., Ph.D., a study co -investigator 
and neurosurgeon at Keck Hospital, with caregiver(s) present. The informed consent process will include a full 
description of the risks and ben efits of the study to ensure the subjects understand that the NPS is an 
investigational research device, with limited supporting clinical information. The responsibilities of the caregiver 
in monitoring and caring for subjects will also be reviewed.  Once the applicant has provided informed consent to 
participate in the study, he or she will be classified as an enrolled study subject and will move to  the eligibility 
phase .   
 
Subjects may withdraw from the study at any time after enrollment at their own req uest, at the request of the 
attending physician, due to adverse events or effects, or due to medical conditions which may not be associated 
with the device ( Section 5.3). 
 
3.4 Eligibility  
 
After informed consent has been obtained, the subject will be evaluated against the study exclusion criteria as 
outlined in Section 5.2 .  This phase of the study involves some tests whose only purpose is study- related, including 
the Rey Auditory Verbal Learning Test, Cognitive Abilities Screening Instrument, Symptom Checklist -90-Revised 
Test, eye exam, urine pregnancy test (if applicable), and ph ysical examination.  With the exception of criteria 
determined by these tests,  exclusion criteria will be evaluated via medical record review, consultation with the 
subject’s primary care physician, and survey of the subject (i.e., verbal interaction).  If  any of these criteria are 
triggered during the eligibility phase, the subject will be withdrawn from the study and will end all study -related 
activities.  Otherwise, if the subject passes all exclusion criteria to the satisfaction of the study investigato rs, the 
subject may continue to the baseline/pre- implant screening phase.  
 
3.5 Baseline/Pre -Implant  
 
Once the subject has been declared eligible to receive the device, a complete medical baseline will be generated.  
This assessment will include a complete medical history, physical examination, complete neurologic exam, vital 
sign measurements, blood samples taken for clinical laboratory tests, and EKG.  The baseline measurements will 
serve to provide a standard against which to monitor the health and wellbeing of the subject throughout the study.  
 
After the baseline measurements have been finalized, surgery for device implantation will be scheduled.  Within 7 
days of the surgical procedure, standard pre- implant procedures will be performed, including a chest X -ray and the 
usual preoperative blood tests (CBC, CMP, AA Chem, UA, RPR, and PT/PTT; for women of childbearing 
potential, a urine pregnancy test).  A pre -surgical MRI will be obtained to prepare for stereotaxic coordination of 
the implantation.  
 
3.6 Implantation  
 
Two NeuroPort Arrays will be provided by Blackrock Microsystems (Salt Lake City, UT).  Each device will be 
sterilized prior to delivery, and will be delivered in a sterile chevron pouch. Device implantation procedures are 
detailed in the NeuroPort Array su rgical manual and are briefly described here.  
 
Pre-surgical MRI images will be used for surgical targeting. At the beginning of surgery, the subject will be placed 
under general anesthesia and a CRW stereotactic frame will be attached to the skull using f our pins. Preoperative 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  18 antibiotics (Vancomycin 1 gram IV) will be administered and the CRW frame will be secured to the operating 
table with a Mayfield clamp. The Radionics stereotactic hardware will be calibrated to the stereotactic coordinates 
obtained f rom the MRI, corresponding to the posterior parietal cortex.  The subject's scalp will be shaved around 
the area of the craniotomy, prepped and draped over the implantation areas. One scalp incision will be made to 
prepare for a single craniotomy over the parietal region, approximately two inches in diameter, providing access to 
both BA5 and AIP.  
 
The first NeuroPort Array will be removed from its packaging and the pedestal screwed to the contralateral skull 
with eight titanium bone screws. The pedestal will be placed away from the craniotomy, contralaterally, toward the 
midline, either slightly anteriorly or posteriorly as indicated by the array placement, and placed so as to provide 
both a safe location and limit discomfort for the subject when the subject’s head is supported (e.g., pillow or chair 
headrest).  Following attachment of the pneumatic inserter to the stereotaxic frame, the dura over somatosensory 
cortex will be opened with a scalpel in preparation for array implantation.  The array will be placed on the cortex 
with the cable orientated in a neutral position so as not to exert force on the array.  The pneumatic inserter will be 
aligned over the back of the array.  The inserter wand will be lowered so that it contacts the NeuroPort Array at the 
peak of cortical pulsations caused by respiration and heart beats.  At the point when the NeuroPort Array reaches 
its highest point the trigger for the pneumatic inserter will be pressed to insert the array into the cortex.  
 
After the first NeuroPort Array is secured, the procedure will be repeated to secure the second pedestal to the 
contralateral skull, and place the second array through the existing craniotomy. The second pedestal will also be 
placed contralaterally to the craniotomy, toward the midline, with enough space between the two pedestals to 
connect both patient cables simultaneously, and with considerations of safety and comfort.  Following the second 
array insertion, the inserter will be removed from the stereotaxic frame.  
 
A duraplasty with Dur agen will be performed at the craniotomy to protect the arrays and the cortex. Titanium 
mesh will be used for a cranioplasty and secured to the skull with titanium screws. The scalp around the pedestals 
will be closed with nylon sutures and dressed with an tibacterial ointment. The CRW frame will then be removed.  
In total, the surgery is expected to last approximately 2 to 5 hours.   
 
After surgery, a protective cap, provided with the array and pedestal, will be screwed onto the threaded head of the 
pedestal to protect the electrical contacts.  The cap will be unscrewed at the beginning of the study sessions by 
trained operators to allow for connection of the patient cable and then replaced at the end of each study session.  
The cap will not be removed other wise, except as necessary for clinical care, and only by trained study personnel 
except in emergencies.  
 
While the subject is recovering from surgery, study personnel will visit with the subject and caregiver to review 
procedures for care of the wound site . 
 
The subject will be transferred post -operatively to the intensive care unit where they will be kept under 
observation for 2 days or until deemed stable for transfer. The subject will receive 24 hours of post -operative IV 
antibiotics.  The subject will u ndergo a CT scan to ensure that there is no intracranial bleeding. Subsequently, they 
will be transferred to the RLANRC acute care unit for 2 days, for further recovery from surgery. During this 
critical post- operative recovery period, at both Keck Hospita l and RLANRC , the subject will be seen twice a day 
by neurosurgeons.  Following this critical care period the subject will be allowed to return home. The subject will 
have follow -up visits for clinical care at one  week, six weeks, and three  months after surgery to monitor the 
healing process.  
 
While the subject has the NPS implant, several procedures will be contraindicated (as specified in the surgical 
manual for the NeuroPort Array: MRI, electrosurgical cautery, diathermy, peripheral nerve stimulation, 
transcranial magnetic stimulation, lithotripsy, radiation therapy, therapeutic ultrasound, and defibrillation. Other 
medical procedures such as dental work, electrolysis, or the implant of another medical device in the body may be 
performed with caution. The  subjects will be instructed to confer with the study doctor before considering such 
procedures.  Each subject will wear an alert bracelet indicating these precautions.  
 
3.7 Healing Period  
 
Following the in -hospital critical care period, the subject will be released to return home.  Wounds will be 
monitored on a weekly basis. Wound care instructions will be provided to the patients and their caregivers.  The 
healing period will last 2 weeks, during which the subject will receive no less than two follow up visit s with the 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  19 neurosurgeon and neurologist while the wound site heals. During this period, the NPS  may be tested briefly for 
functionality, but no study sessions will occur.  
 
3.8 Study Period  
 
During the study period, s tudy sessions will occur 3 -5 times per week at RLA or the subject’s residence. Study 
sessions will provide subjects the opportunity to practice using the NPS to control virtual or physical end effectors 
in a variety of tasks.  S ubject s will continue to rec eive regular clinical follow -up care by the attending physician, to 
occur not less than monthly for the initial three months then every two months.   
 
During study sessions, subjects will be instructed to use motor imagery to perform variations of two basic  tasks 
involving either physical or virtual end effectors. Task 1 (Section 3.8.1 ) involves goal -oriented reaching and/or 
grasping to discrete targets at fixed locat ions in space, while Task 2 (Section 3.8.2) involves continuously variable 
movements.  Both tasks can be performed in a virtual environment or with a physical end effector, such as a 
robotic arm (Section 3.8.3 ). 
 
For each of the two tasks, various imagination and visual presentation methods will be tried to determine the 
method providing the greatest accuracy. For instance, the subject may obtain the most accurate control when 
imagining a hand pointed towar d the target location; alternatively, the subject may obtain higher accuracy when 
imagining arm movement.  In the case of visual presentation, seeing a physical robot arm moving toward a 
physical target location instead of a virtual robot arm moving toward  a virtual target might  lead to  enhance d 
control.  
 
The accuracy with which subjects complete tasks under conditions like these will serve as the primary endpoint for 
measuring effectiveness, and  will be compared against chance.   Additionally, the standard ized Arm Research 
Action Test (ARAT) will be administered and scored by Occupational Therapists at RLANRC as a secondary 
endpoint for measuring effectiveness.  It is expected that performance in the standardized ARAT will serve as a 
guide to understanding how to gauge the significance of the primary accuracy endpoint, and may additionally 
allow some comparison with other methods of intervention.  Finally, subjects will verbally complete a quality -of-
life survey, validated for the paralyzed population, as a third endpoint monitoring effectiveness.  
 
3.8.1 Task 1 –  Fixed Targets  
 
In the training phase of Task 1 , a target object will be presented at one of a number of fixed locations in either 
virtual or physical space . In virtual space, the target object would be vir tually displayed in a 3 -dimensional image 
on a computer screen.  In physical space, a target object would be placed in the subject’s field of view.  The 
subject will be instructed to imagine either reaching to the target and/or grasping the target, the lat ter requiring 
different imagined hand configurations. The neural activity associated with each location will be recorded by the 
NPS computer apparatus and used to construct a database. After sufficient training data has been collected, the 
assessment phase will begin. Experimental work with nonhuman primates has shown that acquiring such training 
data requires 5 -20 minutes per study session.  
 
On each trial of the assessment phase, a target object will be presented at one of the fixed locations  in virtual or  
physical space, and the subject will again be instructed to imagine reaching and/or grasping the target. The NPS 
apparatus will analyze up to one second of neural activity following each target presentation.  It will then decode 
the neural activity using information in the database and read out the imagined, intended target location and/or 
hand configuration. The decoded location and/or configuration will be translated into movement of a virtual or 
physical end effector . A virtual effector could be a 3 -dimensional representation of a robotic arm, which moves 
and interacts in the virtual space in which the target is presented.  A physical effector could be a robotic arm, 
which would be positioned within the subject’s field of view but at least 4 feet distant from the subject.  In both 
settings , the subject will have constant visual feedback about the success of the decoding algorithm and about the 
deviation between what was imagine d and what the algorithm is able to decode.  In addition, auditory feedback 
cues will indicate success or failure.  
 
3.8.2 Task 2 –  Continuous Positioning  
 
In the training phase of Task 2, the subject will be asked not only to imagine the goal of a movement but also the 
continuous transfer from the start location or initial hand configuration to the target location or hand configuration. 
Such tasks will include tracing (by imagin ed arm and hand movements) the trajectory of a physical or virtual 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  20 robotic hand moving to a target location; or, to imagine mimicking the fine movements of a physical or virtual 
hand closing around or manipulating an object. Neural activity during these time frames will be recorded and used 
to construct a database. After sufficient training data has been collected, the assessment phase will begin. Again, 
this training data collection is estimated to take 5 -20 minutes per session.  
 
On each trial of the assessment phase a physical or virtual effector will be presented in a starting configuration and 
the subject will be instructed to imagine the motor process to control the effector’s trajectory to acquire a target 
location or hand configuration. Neural activity recorded during each trial will be compar ed to the database in near 
real-time and used to update the predicted location and shape of the hand.  
 
3.8.3 End Effector  
 
Study subjects will use the Modular Prosthetic Limb (MPL), a robotic arm designed through the Johns Hopkins 
University (JHU) Applied Physic s Laboratory (APL).  The MPL has 17 degrees of freedom, and, fully extended, 
the MPL is 790.7 mm (just over 2’7”) long.  It was designed to approximate the function of a human arm, and its 
ranges of motion were specified to match those of a human arm as cl osely as possible.  
 
 
Figure 3 -2.  The JHU/APL Modular Prosthetic Limb (MPL).  
 
The MPL will be bolted to a steel frame at least four feet from the subjects, such that it will not be possible for the 
MPL to physically interact with a subject during a task .  When a task is not active, the MPL will be powered off, 
or fixed in position by software and unable to move.  The MPL will be controlled via computer.  There will be no 
physical or electrical feedback pathways from the MPL back to the subject.  The subj ect will use only visual 
feedback to monitor operation of the limb.  
 
Because there will be no physical, electrical, or other interaction between the subject and the MPL (except for 
visual observation), there is no context in which the safety of the Neural Prosthetic System (NPS) is affected by 
the presence of the MPL as an end effector.  The MPL is a modular substitute for a virtual environment and 
represents no additional risk or need for additional safety assessment.  
 
A computerized, three -dimensional model of the MPL is available as a virtual end effector for the NPS. The 
components  of physical tasks , such as blocks, balls, shelves, washers, etc., will be replicated in the virtual 
environment so that the tasks can be administered in both the virtual an d the physical environments.   Alternatively, 
a computer cursor could be used as a virtual end effector for simple tasks.  
 
3.9 Explantation  

Doc: Proform   
 
Version date: 04/15/12  
Confidential  21  
Explantation could occur earlier than at the conclusion of the study period if withdrawal criteria are met (Section 
5.3). In such a case, t he NPS would be explanted unless clinical or ethical concerns determined by the sponsor -
investigator and clinical team mandate otherwise.  
 
In the default (and expected) case, the NPS implant will be explanted at the conclusion of the study period.  In the 
event of explantation, the subject will be returned to the operating room where peri -operative antibiotics will be 
administered. At the beginnin g of surgery, the subject will be placed under general anesthesia and a CRW 
stereotactic frame will be attached to the skull using four pins. Preoperative antibiotics (Vancomycin 1 gram IV) 
will be administered and the CRW frame will be secured to the oper ating table with a Mayfield clamp. The scalp 
will be shaved, prepped, and draped over the incision site and the pedestals. The incision will be re- created 
initially over the craniotomy sites, and the scalp will be elevated over the titanium mesh. Bacterial  cultures will be 
obtained if found to be necessary by the attending neurosurgeon. The screws securing the mesh and the titanium 
mesh itself will be removed. A plane of dissection under the dura and Duragen will be established. The electrode 
arrays will be  removed by hand from the cortex. This portion of the wound will be irrigated with antibiotic flush, 
and a new piece of Duragen will be placed over the defect in the dura. A new titanium mesh will be used for a 
cranioplasty and secured to the skull with titanium screws. All plates securing the array cables leading to the 
pedestal will be removed, and the electrode arrays will be cut from their cables and saved for analysis. The 
incision over the craniotomy will then be closed with 3 -0 nylon sutures. An inci sion will then be made around the 
pedestal. Bacterial cultures will again be obtained, if found to be necessary by the attending neurosurgeon. The 
pedestal screws and the pedestal, along with the attached cables will be removed. The wound edges around the 
pedestal will be debrided to viable tissue. This portion of the wound will also be irrigated with antibiotic flush and 
closed with 3 -0 nylon suture. Both wounds will be dressed with antibiotic ointment and sterile gauze, and the 
Mayfield holder will be rem oved.  
 
The subject will be transferred post -operatively to the intensive care unit where they will be kept under 
observation for 2 days. The subject will undergo a CT scan to ensure that there is no intracranial bleeding. The 
subject will also receive a f inal MRI for comparison with the pre -implant MRI.  Subsequently, the subject will be 
transferred to the RLANRC acute care unit for 2 days, for further recovery from surgery. During this critical post -
operative recovery period, at both Keck Hospital and RLA NRC, the subject will be seen twice a day by 
neurosurgeons.  Following this critical care period the subject will be allowed to return home.  
 
3.10 Follow -up Care  
 
After being discharged from the hospital, the subject will return home. The subject will have foll ow-up visits for 
clinical care at one  week, six weeks, and three  months after surgery to monitor the healing process. The subject’s 
experience in the study will be evaluated by a questionnaire which will assess health, safety, adaptation, and 
capabilities of the NPS.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  22 4.0 Device Information  
 
4.1 Device Overview  
 
The Neural Prosthetic System (NPS) is a medical device implanted into the parietal cortex for the purpose of 
providing severely paralyzed individuals novel capabilities for interacting with an environment. The NPS 
comprises two NeuroPort Arrays.  
 
4.2 IDE Number  
 
The IDE number of the NPS is G120096.  
 
4.3 NeuroPort Array  
 
The NeuroPort Array is manufactured by Blackrock Microsystems, Salt Lake City, UT, USA.  
 
NeuroPort Arrays allow for the local recording of cerebral cortex. Key features include sterile, single use 
electrodes that provide access to a localized population of individual cells. The main component of the NeuroPort 
Array is an array comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm 
silicon base that is 0.25 mm thick. Each micro electrode is insulated with Parylene -C polymer and is electrically 
isolated from neighboring electrodes by non -conducting glass. Each microelectrode has a platinum tip that is 100 -
200 microns in length and offers impedance values from 100 –800 kilo -ohms. Of  the 100 electrodes, 96 are wire 
bonded using 25 µm gold alloy insulated wires collectively sealed with a silicone elastomer.  The wire bundle is 
potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal 
(percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum 
reference wires are also attached to the Patient Pedestal.  The Patient Pedestal is 19 mm wide at the skin interface.  
 
Currently, the NeuroPort Array is cleared for temporary (<30 days) recording and monitoring of brain electrical 
activity. For this study, two NeuroPort Arrays will be used for long -term (53 weeks) passive recording of cortical 
activity.  
 
Two other components will be used in support of the NeuroPort Array: the Array Inserter, and the NeuroPort 
Biopotential Signal Processor : the Array Inserter for the NeuroPort Array (Section 4.3.1 ), and the NeuroPort 
Biopotential Signal Processor (Section 4.3.2 ). 
 
4.3.1 Array Inserter for the NeuroPort Array  
 
The Array Inserter is manufactured b y Blackrock Microsystems, Salt Lake City, UT, USA.  
 
The array inserter allows for the rapid insertion of a surface aligned array into cerebral cortex. Key features 
include: a multiple -use trigger -actuated pneumatic piston, and a pressure source. Piston stroke length can be 
adjusted, which prevents excessive  dimpling of cortical tissues upon insertion.  Piston actuation is achieved 
through an actuated chamber that is pressurized with a 120 VAC driven pump.  The power source is patient 
isolated with a hospital grade isolation transformer. This inserter is part of the 510(k) cleared device, the 
NeuroPort Array.  
 
4.3.2 NeuroPort Biopotential Signal Processor  
 
The NeuroPort Biopotential Signal Processor is manufactured by Blackrock Microsystems, Salt Lake City, UT, 
USA.  
 
Neural signals read out by the passive implant d evice are recorded via the NeuroPort Biopotential Signal 
Processor. The NeuroPort Biopotential Signal Processor allows for the recording of up to 128 channels of activity.  
Key features include: an optically isolated amplifier capable of recording 128 chan nels at 30 kHz with 16 -bit 
resolution.  
 
The power source is 120 VAC through a hospital grade isolation transformer. The NeuroPort Biopotential Signal 
Processor complies with the relevant safety standards for intra -operative and hospital monitoring settings : IEC 
60601- 2-26, IEC 60601- 1-2, UL 2601- 1, CAN/CSA- C22.2 no. 601.1- M90.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  23  
The NeuroPort Biopotential Signal Processor has received 510(k) clearance for use. It will not be modified in any 
way from its original 510(k) clearance for use.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  24 5.0 Selection and Withdrawal of Subjects  
 
5.1 Inclusion Criteria  
 
Table 5 -1 outlines the inclusion criteria which will be applied to study applicants, as well as the method of 
evaluating each criterion and the threshold for each criterion.  The methods used to evaluate inclusion criteria 
consist of verbal discussion , medical record review, and consultation with the subject’s primary care physician.  
 
Table 5 -1.  Inclusion criteria, methods of evaluation, and thresholds for inclusion.  
Criterion  Method of Evaluation  Threshold  
High cervical spinal lesion  Medical Records  History of spinal lesion (C4 and 
above), with 0/5 distal arm 
muscle strength in both arms:  
C5 – Deltoid and biceps  
C6 – Wrist extensors  
C7 – Triceps  
C8 – Finger flexors  
T1 – Finger abductors  
 
Occurred at least one year prior 
to enrollment  
 
Stable for three months prior to 
enrollment (no signs of 
improvement)  
Age Medical Records  18-65 years  
Provide informed consent  Consultation with Physician  Must be willing and able  
Understand and comply with 
instructions in English  Consultation with Physician  Must be able  
Communicate via speech  Consultation with Physician  Must be able  
Surgical clearance  Consultation with Physician  Must be cleared  
Life expectancy  Consultation with Physician  Greater than 12 months  
Travel up  to 60 miles to study 
locations up to five days per week for 
the duration of the study  Verbal discussion  Must be willing and able  
Caregiver monitor for surgical site 
complications and behavioral changes 
on a daily basis  Verbal discussion  Caregiver must be  willing and 
able 
Psychosocial support system  Verbal discussion  Must be present and stable  
 
5.2 Exclusion Criteria  
 
Table 5 -2 outlines the exclusion criteria which will be applied to study subjects, as well as the method of 
evaluating each criterion and the threshold for each criterion.  The methods used to evaluate exclusion criteria 
consist of some tests (as specified in Table 5 -2), survey (i.e., verbal and written interaction with patient), medical 
record review, consultation with the subject’s primary car e physician, and physical examination.  
 
Table 5 -2.  Exclusion criteria, methods of evaluation, and thresholds for exclusion.  
Criterion  Method of Evaluation  Threshold  
Presence of memory problems  Rey Auditory Verbal Learning Test  Age-dependent (Appendix, 
section 18.5) 
Intellectual impairment  Cognitive Abilities Screening 
Instrument (CASI)  Score of 26 or less  
Psychotic illness or chronic 
psychiatric disorder, including major 
depression if untreated  Symptom Checklist -90-Revised Test  diagnosis of Axis I or Axis II  
Poor visual acuity  Snellen chart  20/30 or lower  
Pregnancy  Urine Pregnancy Test  Positive (Pregnant)  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  25 Active infection or unexplained fever  Physical Examination  Evidence of either  
Scalp lesions or skin breakdown  Physical Examination  Evidence of either  
HIV or AIDS infection  Medical Records, blood work  Positive (infected)  
Active cancer or chemotherapy  Medical Records  History of cancer in past 12 
months, or evidence of need for 
chemotherapy during study  
Diabetes  Medical Records, blood work  Any 
Autonomic dysreflexia  Medical Records  History in past 3 months  
History of seizure  Medical Records  Any 
Implanted hydrocephalus shunt  Medical Records  Any 
Previous neurosurgical history 
affecting parietal lobe function  Medical Records  Any 
Medical conditions contraindicating 
surgery and chronic implantation of a 
medical device  Medical Records  osteomyelitis, diabetes, 
hepatitis, any autoimmune 
disease/disorde r, epilepsy or 
history of seizures of any kind, 
skin disorders causing excessive 
skin sloughing or poor wound 
healing, blood or cardiac 
disorder requiring chronic anti -
coagulation  
Prior cranioplasty  Medical Records  Any 
Unable to undergo MRI or anticipate d 
need for MRI during study  Medical Records, Consultation with 
Physician  Any 
Nursing an infant or unwilling to 
bottle -feed infant  Medical Records, Survey  Any 
Chronic oral or intravenous use of 
steroids or immunosuppressive 
therapy  Medical Records, Survey  Any 
Suicidal ideation  Medical Records, Survey  History in past 12 months  
Drug or alcohol dependence  Survey  History in past 12 months  
Planning to become pregnant, or 
unwilling to use adequate birth 
control  Survey  Any plan for pregnancy, or 
unwilling to use birth control  
 
5.3 Withdrawal Criteria  
 
Withdrawal is premature conclusion, which may occur at any time. Withdrawal is discouraged, but is a right of the 
subject.  If the subject withdraws, he or she cannot continue to use the NPS.  The clinical team and sponsor -
investigator will determine whether to explant the device based on clinical and ethical considerations and the 
nature of the withdrawal.  If the subject withdraws and has all devices explanted, there is no need for further 
physician monitoring of t he device, and the patient will receive the standard clinical follow -up care (follow -up 
visits at one week, six weeks, and three months post -surgery) . 
 
The withdrawal criteria are:  
 
• Patient request  
• Attending physician (neurosurgeon, neurologist) request  
• Serious infection around the percutaneous connector  
• 53 weeks of implantation, unless patient opts to retain device  
• Pregnancy  
• Onset of epilepsy  
• Significant change in neurological exam  
• Development of serious adverse events, physical or psychological, including negative behavioral 
symptoms, major depression, or suicidal ideation 
• Intracranial infection unresponsive to antibiotic treatment  
• Development of intracranial hematoma requiring evacuation  
• Need for urgent MRI of any kind (brain or body)  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  26  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  27 6.0 Stratification/Descriptive Factors/Randomization Scheme  
 
Because this study is structured to evaluate the feasibility of the NPS, there are no elements of stratification or 
randomization involved in subject selection or device administration.  Subjects will be sel ected who display 
symptoms characteristic of high (C4) spinal lesion.  Each of these subjects will receive the same device, and will 
participate in the same tasks to evaluate the effectiveness of the device.  The health of each subject, including the 
area around the implant, will be evaluated in the same way for both subjects.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  28 7.0 Study Agent Administration or Intervention and Toxicity Management Plan  
  
7.1 Device Administration  
 
Each subject in this study will receive the same device.  The device consists of tw o NeuroPort Arrays implanted in 
the posterior parietal cortex.  One array will be implanted in Brodmann’s area 5, and the second array will be 
implanted in the anterior intraparietal area.  Each subject will undergo the same evaluations to monitor the safe ty 
of the implanted device.  Each subject will participate in the same set of tasks designed to evaluate the 
effectiveness of the  device.  
 
7.2 Intervention Plan  
 
There are no alternative therapies available for this device, and the condition which predicates this device 
(paralysis) is not acutely life -threatening, so a slow treatment or absence of treatment does not constitute undue 
risk to the subject requiring in tervention.  However, the presence of the device does present increased risk to the 
subject, particularly in terms of the risk of infection.  Thus, it may be determined by the study sponsor that the 
device cannot be made to work without significant surgica l revision or other risk -laden procedure;  and, if it is so 
determined, the study sponsor and co -investigators may opt at their discretion to withdraw the subject from the 
study  as a means of intervention to cease ongoing study- related risk . 
 
7.3 Toxicity Mange ment Plan  
 
The NeuroPort Arrays are approved by the FDA to be in prolonged contact with CSF, bone/blood and tissue, i.e., 
for 30 days or less.  (For the purposes of this study, an investigational device exemption has been obtained which 
approves permanent contact with CSF, bone/blood and tissue).  Additionally, the NeuroPort Arrays are constructed 
using materials with a history of biocompatibility, such as titanium.  In order to obtain 510(k) approval for 
prolonged contact, the NeuroPort Array was required to undergo a suite of tests determining its biocompatibility; 
the device was determined to be biocompatible for its originally intended use .  Furthermore, an extensive body of 
literature reviewing the CerePort Array in animals and, and a smaller body of wo rk reviewing results of the 
BrainGate clinical study sequence, have collectively demonstrated no chronic toxicity (see Section 1.3.1  for a 
review of this evidence).   The sponsor and investigators of this study take the evidence at hand to support the view 
that the device is not toxic.  Therefore, this study does not include any toxicity management strategies.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  29 8.0 Assessment of Effectiveness and S afety  
 
8.1 Side Effects Mo nitoring  
 
8.1.1 Side Effects Monitored During Study  
 
The primary long -term risk associated with the NPS is that of infection.  Infection could develop around the 
percutaneous connectors, or it could develop intracranially.  Thus, study subjects will be monitored  throughout the 
study to watch for signs and symptoms of both superficial and intracranial infection.   
 
Monitoring for superficial infection will include participation of the subjects’ caregivers as well as study 
physicians.  The caregivers will be trained to observe and maintain the wound site on a daily basis.  Physicians 
will check the wound site monthly over the course of the study.  
 
Monitoring for intracranial infection will also include participation of the subjects’ caregivers as well as study 
physi cians.  Caregivers will be trained to watch for signs of intracranial infection such as functional deficits and 
seizure.  Physicians will conduct thorough examinations of study subjects, including both physical and 
neurological, on a monthly basis througho ut the study.  
 
8.1.2 Side Effects Monitored After Study  
 
As is routine for patients who undergo brain surgery, the patient will be seen for follow -up visits at one week, six 
weeks, and three months following the explant surgery.  At these visits, the attending physician will execute a full 
physical and neurological examination to test for any adverse events or effects which may have occurred.  
 
8.2 Adverse Event Reporting  
 
8.2.1 Adverse Event Definitions  
 
Adverse event . Any untoward medical occurrence in a clinical study o f an investigational device; regardless of the 
causal relationship of the problem with the device or, if applicable, other study treatment or diagnostic product(s).  
 
Associated with the investigational device or, if applicable, other study treatment or diagnostic product(s) .  There 
is a reasonable possibility that the adverse event may have been caused by the investigational device or, if 
applicable, the other study treatment or diagnostic product(s).  
 
Disability .  A substantial disruption of a person’s ability to conduct normal life functions.  
 
Life-threatening adverse event .  Any adverse event that places the subject, in the view of the sponsor -investigator, 
at immediate risk of death from the event as it occurred (i.e., does not include an adverse even t that, had it actually 
occurred in a more severe form, might have caused death).  
 
Serious adverse event . Any adverse event that results in any of the following outcomes: death, a life -threatening 
adverse effect, inpatient hospitalization or prolongation o f existing hospitalization, a persistent or significant 
disability/incapacity, or a congenital anomaly/birth defect.  
 
• Hospitalization  shall include any initial admission (even if less than 24 hours) to a healthcare facility as a 
result of a precipitating c linical adverse event; to include transfer within the hospital to an intensive care unit.  
Hospitalization or prolongation of hospitalization in the absence of a precipitating, clinical adverse event (e.g., 
for a preexisting condition not associated with a  new adverse event or with a worsening of the preexisting 
condition; admission for a protocol -specified procedure) is not, in itself, a serious adverse effect.   
 
Unexpected adverse event .  Any adverse event, the frequency, specificity or severity of which  is not consistent 
with the risk information described in the clinical study protocol(s), as amended.  
 
Unanticipated adverse device event .  Any serious adverse event on health or safety or any life -threatening problem 
or death caused by, or associated with , a device, if that event, problem, or death was not previously identified in 
nature, severity, or degree of incidence in the investigational plan (including a supplementary plan or application), 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  30 or any other unanticipated serious problem associated with a  device that relates to the rights, safety, or welfare of 
subjects.  
 
8.2.2 Eliciting Adverse Event Information  
 
Clinical study subjects will be routinely questioned about adverse events at study visits.  
 
8.2.3 Recording and Assessing Adverse Events  
 
All observed or volunteered adverse events (serious or mild) and abnormal test findings, regardless of treatment 
group, if applicable, or suspected causal relationship to the investigational device or, if applicable, other study 
treatment or diagnostic pro cedure(s) will be recorded in the subjects’ case histories.  For all adverse events, 
sufficient information will be pursued and/or obtained so as to permit 1) an adequate determination of the outcome 
of the event (i.e., whether the event should be classifi ed as a serious adverse event) and; 2) an assessment of the 
causal or potential causal relationship between the adverse event and the investigational device or, if applicable, 
the other study treatment or diagnostic product(s).    
 
Adverse events or abnorm al test findings felt to be associated or possibly associated with the investigational 
device will be classified as serious or mild and will be followed until resolved or stabilized at a level acceptable to 
the sponsor -investigator.  
 
8.2.4 Abnormal Test Findings  
 
An abnormal test finding will be classified as an adverse event if one or more of the following criteria are met:  
 
• The test finding is accompanied by clinical symptoms.  
• The test finding necessitates additional diagnostic evaluation(s) or medical/surgical intervention; 
including significant additional concomitant drug or other therapy.  (Note: simply repeating a test finding, 
in the absence of any of the other listed criteria, does not constitute an adverse event.)  
• The test finding leads to a change in study dosing or exposure or discontinuation of subject participation 
in the clinical study.  
• The test finding is considered an adverse event by the sponsor -investigator.  
 
8.2.5 Causality and Severity Assessment  
 
The sponsor -investigator will promptly review documented adverse events and abnormal test findings to determine 
1) if the abnormal test finding should be classified as an adverse event; 2) if there is a reasonable possibility that 
the adverse event was caused by the investigational device or, if applicable, o ther study treatment or diagnostic 
procedure(s); and 3) if the adverse event meets the criteria for a serious adverse event . 
 
If the sponsor -investigator’s final determination of causality is “unknown and of questionable relationship to the 
investigational  device or, if applicable, other study treatment or diagnostic procedure(s) are deemed necessary”, 
the adverse event will be classified as associated or possibly associated with the use of the investigational device 
or study treatment or diagnostic drug pr ocedure(s)  for reporting purposes.  If the sponsor -investigator’s final 
determination of causality is “unknown but not related to the investigational device or, if applicable, other study 
treatment or diagnostic procedure(s)”, this determination and the ra tionale for the determination will be 
documented in the respective subject’s case history.  
 
8.2.6 Reporting of Adverse Events to the FDA  
 
The sponsor -investigator will submit a completed FDA Form 3500A to the FDA’s Center for Devices and 
Radiological Health for any observed or volunteered adverse event that is determined to be an unanticipated 
adverse device event.  A copy of this completed form will be provided to all participating sub -investigators.   
 
The completed FDA Form 3500A will be submitted to the FDA as soon as possible and, in no event, later than 10 
working days after the sponsor -investigator first receives notice of the adverse event.  
 
If the results of the sponsor -investigator’s follow -up evaluation show that an adverse event that was initially 
determined to not constitute an unanticipated adverse device event does, in fact, meet the requirements for 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  31 reporting; the sponsor -inves tigator will submit a completed FDA Form 3500A as soon as possible, but in no event 
later than 10 working days, after the determination was made.  
 
For each submitted FDA Form 3500A, the sponsor -investigator will identify all previously submitted reports th at 
addressed a similar adverse event experience and will provide an analysis of the significance of the newly reported 
adverse event in light of the previous, similar report(s).  
 
Subsequent to the initial submission of a completed FDA Form 3500A, the spons or-investigator will submit 
additional information concerning the reported adverse event as requested by the FDA.  
 
8.2.7 Reporting of Adverse Events to the Responsible IRB  
 
In accordance with applicable policies of the reviewing Institutional Review Boards (IRBs ), the sponsor -
investigator will report, to all associated IRBs, any observed or volunteered adverse event that is determined to 
meet all of the following criteria: 1) associated with the investigational device or, if applicable, other study 
treatment or d iagnostic product(s);  2) a serious adverse event ; and 3) an  unexpected adverse event .  Adverse event 
reports will be submitted to the IRB in accordance with the respective IRB procedures.  
 
Applicable adverse events will be reported to the IRB as soon as p ossible and, in no event, later than 10 calendar 
days following the sponsor -investigator’s receipt of the respective information.  Adverse events which are 1) 
associated with the investigational device or, if applicable, other study treatment or diagnostic  product(s);  2) fatal 
or life -threatening; and 3) unexpected  will be reported to the IRB within 24 hours of the sponsor -investigator’s 
receipt of the respective information.  
 
Follow -up information to reported adverse events will be submitted to the IRB as  soon as the relevant information 
is available.  If the results of the sponsor -investigator’s follow -up investigation show that an adverse event that 
was initially determined to not require reporting to the IRB does, in fact, meet the requirements for repo rting; the 
sponsor -investigator will report the adverse event to the IRB as soon as possible, but in no event later than 10 
calendar days, after the determination was made.  
 
8.2.8 List of Adverse Events  
 
The following list comprises adverse events which could oc cur. 
 
8.2.8.1  CNS: Infection/Vascular/CSF  
• CNS hematoma (e.g., subdural, epidural)  
• CSF Leakage  
• Deep Vein Thrombosis (DVT)  
• Encephalitis  
• Hemorrhage  
• Intracranial hemorrhage  
• Meningitis  
• Stroke  
 
8.2.8.2  Wound (surgery -related)  
• Bleeding  
• Drainage  
• Edema  
• Infection (superficial)  
• Irritation  
• Soreness  
• Pain 
 
8.2.8.3  Pain  
• Acute, deep  
• Acute, superficial  
• Chronic, deep  
• Chronic, superficial  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  32 • Headache 
 
8.2.8.4  Seizure  
• New seizure  
• Onset of epilepsy  
• Status epilepticus  
 
8.2.8.5  Cognitive Memory  
• Attention/concentration difficulty  
• Confusion 
• Memory difficulty  
• Psychomotor  slowing/encephalopathy  
 
8.2.8.6  Mood/Psychological  
• Agitation/irritability  
• Anxiety/nervousness  
• Depression  
• Emotional liability  
• Personality change  
• Psychosis  
 
8.2.8.7  Language  
• Dysarthria  
• Aphasia (e.g., Dysnomia, Dysphasia)  
 
8.2.8.8  Movement/Coordination  
• Ataxia  
• Coordination difficulties  
• Dyskinesia/Dystonia  
• Involuntary movements (e.g., twitching, myoclonus, chorea)  
• Tremor  
• Weakness (paresis)  
 
8.2.8.9  Sensory  
• Loss of sensation (e.g., numbness, loss of proprioceptive/vibratory sensation)  
• Loss of sight  
• Vertigo/dizziness  
 
8.2.8.10  Coma/Death 
• Coma  
• Death 
 
8.2.8.11  Allergy/Immunologic  
• Allergic reaction (e.g., wound care cleaning solution)  
• Rejection (e.g., sensor or percutaneous connector)  
 
8.2.8.12  Constitutional/Systemic  
• Appetite change  
• Edema  
• Fatigue  
• Fever  
• Flu 
• Hematologic  
• Insomnia/other sleep disorders  
• Night sweats  
• Weight change  
 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  33  
8.2.8.13  Tumor/Cancer  
• Cancer, malignant  
• Mass/lesion, benign  
 
8.2.9 Withdrawal of Subjects Due to Adverse Events  
 
An adverse event may be serious in nature and require the subject to withdraw from the study.  The severity of the 
adverse event, and whether it constitutes a reason for withdrawal from the study, will be determined by the clinical 
team and sponsor -investigator.  Unless otherwise indicated by the clinical team and sponsor -investigator, the 
device will be explanted before the subject is withdrawn  from the study.  
 
8.3 Data Monitoring Committee  
 
Aptiv Solutions, Inc. (Aptiv) will perform data monitoring over the course of the study.  
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  34 9.0 Clinical and Laboratory Evaluations and Clinical Calendar  
 
See Appendix, Section 18.1.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  35 10.0 Criteria for Evaluation and Endpoint Definitions  
 
The objectives of this study are to evaluate the safety and effectiveness of the NPS.  Each of these objectives will 
be measured quantitatively as defined in Table 10 -1 and described in this section.   
 
Table 10 -1.  Safety and Effectiveness Endpoints  
Objective  Hypothesis  Method of Evaluation  Time of 
Assessment  Comparisons Made  
To evaluate 
the safety of 
the NPS 
implant  Primary endpoint – 
implantation will not be 
associated with 
infection or irritation  Inspection of subject’s 
scalp for evidence of 
reddening or 
discharge; review of 
new symptoms 
including possible 
fever, headache, visual 
or aud itory changes, 
or change in mood or 
behavior; serial 
neurologic exams  Immediately 
after 
implantation 
and weekly 
thereafter  The condition of the 
area will be 
compared with its 
condition on previous 
visits  
 
History will be 
obtained regarding 
new symptoms  
 
Neurologic exam will 
be compared to 
baseline neuro exam  
 Secondary endpoint – 
the Severe Adverse 
Event (SAE) rate will 
not rise above 1% for 
any study subjects.  The SAE rate will be 
calculated as the 
number of SAEs per 
implant -days.  The SAE rate 
will be 
available on a 
daily basis 
throughout the 
study.  The SAE rate will be 
continuously 
compared to the 1% 
threshold level.  
To evaluate 
the 
effectiveness 
of the NPS  Primary endpoint –
patient control over the 
end effector (virtual or 
physical), as measured 
by accuracy, will be 
significantly greater 
than chance when using 
the NPS  Calculated by the NPS 
computer apparatus  At the end of 
every study 
session  Assessments will be 
compared with 
chance  
 Secondary endpoint – 
Action Research Arm 
Test (ARAT) scores 
will im prove over the 
course of the trial when 
controlling the virtual 
or physical robotic arm  ARAT administered 
by occupational 
therapists  At 10 -week 
intervals 
starting at 
week 3.  Scores will be 
compared to the 
baseline, i.e., the first 
score from week 3.  
 Tertiary endpoint – 
using the NPS with 
either a virtual or 
physical end effector 
will result in significant 
increases in the 
subject’s quality of life  Quality of Life 
Inventory (QOLI) 
administered by the 
NPS operator  During 
prescreening 
(baseline) and 
every m onth 
subsequent to 
implantation  Monthly QOLI score 
will be compared 
against baseline  
 
 
10.1 Safety Endpoints  
 
 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  36 10.1.1  Infection and Irritation  
 
Infection and irritation are the most serious risks identified for the NPS, and as such the absence of both serves as 
a primary safety endpoint for the study.  The implant sites will be monitored by visual inspection of the wound 
margin, verbal survey of the subject, and neurologic exam.  
 
10.1.2  SAE Rate  
 
The severe adverse event (SAE) rate is the secondary safety endpoint .  The i ndicated SAE rate threshold, at 1% 
SAEs per implant -days, was established based on literature describing adverse events for similar procedures ( 107, 
108). 
 
10.2 Effectiven ess Endpoints  
 
Three methods will be used to assess the effectiveness of the NPS while controlling virtual and physical end 
effectors : comparison of task performance to the level of chance at each study session, standardized tests applied 
at 10 -week intervals, and the Quality -of-Life Inventory (QOLI) applied at 4 -week intervals.  
 
10.2.1  Comparison of Task Performance to the Level of Chance 
 
The design of study tasks as described in the original IDE application allows for virtual or physical end effectors.  
In Tas k 1 –  Discrete Selection, an object will be placed in the subject’s field of view and the subject will be 
instructed to imagine reaching and/or grasping the target object.  Each instruction to reach to a target object will be 
considered the beginning of a trial.  If the subject then operates the MPL according to the instructions, the trial will 
be considered successful; otherwise, the trial will be considered unsuccessful.  Then, the percentage of successful 
trials compared to the level of chance will serve to assess the use of the MPL in the task.  In Task 2 –  Continuous 
Positioning, the same method will be used to assess the use of the MPL relative to the level of chance.  
 
10.2.2  Standardized Tests  
 
Two commonly -used, standard tests have been selected by which the use of robotic arm will be evaluated: the 
Action Research Arm Test (ARAT) and the Canadian Occupational Performance Measure (COPM).  These tests 
will be evaluated at 10 -week intervals throughout the study beginning at week 3 (i.e., after the healing pe riod), for 
a total of six evaluations.  The ARAT is widely used in therapy with upper -extremity -disabled populations and 
may allow for direct comparison with other interventions.  The COPM, also widely used, is a subject -centric 
paradigm designed to measur e the subject’s perceived performance.  
 
The ARAT ( 109) was designed to provide a rapid, reliable test to assess recovery of upper limb function following 
cortical damage.  It is composed of four subtests, including grasp, grip, pinch, and gross movement; however, 
because the gr oss movement test would require interaction between the robotic arm and the subject, it will not be 
used.  Scoring will be adjusted accordingly, with a four -point scale (0 -3) accorded to each of 16 other individual 
tasks (see ARAT Clinical Note in Section XX ).  The remaining tasks will evaluate gross through fine hand and 
arm function.  
 
The COPM ( 110) was designed to evaluate perceived occupational performance across categories including self -
care, productivity and leisure.  It is a semi -structured process in which the therapist and subject identify problem 
areas, the subject rates the importance of each problem, and the subject scores his or her performance in the 
problem areas.  Then, after a period of intervention, performance is re- assessed and a plan for continuation of 
treatment is formulated.  Problem areas applicable for this study could be, for  example, grasping or pinching with 
the extracorporeal device.  Scoring is performed on a 10 -point scale (0 -9) with 0 being “least important” and 9 
being “most important.”  
 
10.2.3  Quality -of-Life Inventory  
 
The Quality of Life Inventory ( QOLI ) was designed to inc orporate both field -standard quality -of-life 
measurements as well as study -specific measurements.  The QOLI is attached to this supplement as a clinical note 
in Section XX.  In the QOLI clinical note, Section 1 is comprised of questions which are intended to capture NPS -
related quality -of-life measurements.  These questions were developed specifically for this study, but are 
potentially relevant for evaluation of other brain -controlled prostheses.  Section 2 is the Satisfaction With Life 
Doc: Proform   
 
Version date: 04/15/12  
Confidential  37 Scale (SWLS) ( 111), a standard questionnaire for m easuring global life satisfaction.  Section 3 is the Subjective 
Quality of Life (SQOL) ( 112), a single -item, subjective measure of quality  of life.  Both the SWLS and SQOL 
have been validated in populations of paralyzed patients at RLANRC .  The SWLS is a standard  in the field for 
measuring global life satisfaction.  Thus, the QOLI incorporates both study -specific quality -of-life measurements 
as well as standard instruments for measuring life satisfaction and quality of life in paralyzed populations.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  38 11.0 Special Ins tructions  
 
N/A.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  39 12.0 Data Collection and Monitoring  
 
12.1 Case Report Forms  
 
Case Report Forms (CRF) will be used to collect all data from source documents, such as Clinical Notes, Medical 
Records, and Surveys.  Data in CRFs will be verified against data in the source documents and approved (via 
digital signature) by the sponsor -investigator.  CRFs will serve as the official record for the clinical study.  CRFs 
are listed and described in Table 12 -1. 
 
Table 12 -1.  Case report forms.  
CRF Name  Source Document  
Adve rse Event  Clinical Note  
Action Research Arm Test (ARAT)  Clinical Note  
Canadian Occupational Performance Measure (COPM)  Clinical Note  
Conclusion/Withdrawal  Clinical Note  
Consent Information  Clinical Note; Informed Consent Document  
Inclusion/Exclusion  Clinical Note; Medical Records  
Initial Office Appointment  Clinical Note  
Office Appointment  Clinical Note  
Quality -of-Life Index  Clinical Note  
Study Session  Clinical Note  
Surgical Procedure  Clinical Note; Medical Records  
 
12.2 Source Documentation and Timeliness of CRF Completion  
 
Source documents are reports or records of medical and health information that are required to be filed in the 
subject binder or must be made available during monitoring visits or audits.  Source documents provide 
information necessary to complete CRFs.  To ensure timely completion, CRFs should be completed within 30 days 
of contact with the subject.  
 
Clinical Notes are provided to the clinical site.  Information recorded in a Clinical Note is transcribed into the 
corresponding CRF.  The person recording the data must sign each page of the Clinical Notes.  Any edits must be 
redlined, initialed, and dated.  
 
The quality of life inventory (QOLI) is provided to the subject to complete during investigation appointments.  
The inventory itself is the source document.  Data is entered into the corresponding CRF.   
 
12.3 Retention of Study Record  
 
Study records will be retained for the duration of the study at a minimum.  Thereafter, study records will be 
maintained for such time as is needed to provide a full report on the results of the clinical study.  Medical records 
will remain with the clinical record on file for the study subject.  
 
12.4 Data Management  
 
CRFs will be collected and stored in a clinical data management system.  Eac h CRF will be uniquely and 
appropriately named to avoid confusion.  Data will be checked for typographical and logical errors, and 
investigators contacted if clarification is required.   
 
12.5 Data Monitoring  
 
Aptiv Solutions, Inc. (Aptiv) has been contracted t o perform data monitoring for this clinical study.  
 
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  40 13.0 Statistical Considerations  
 
13.1 Study Objectives  
 
This feasibility study is designed to evaluate the safety and effectiveness of the NPS, a device which records brain 
activity from the posterior parietal c ortex.  The safety of the device will be evaluated by monitoring the health of 
the implant over the course of the study.  The effectiveness of the device will be evaluated by monitoring accuracy 
in certain tasks, as the subjects attempt use their thoughts to control external effectors, and by monitoring the 
subjects’ quality of life, as measured by the quality -of-life index (QOLI) throughout the study.  Two subjects will 
be enrolled in this study.  Each subject will serve as his or her own control.  
 
13.2 Accrual  
 
The expected accrual rate for this study is 0.06% (two subjects enrolled out of a population of approximately 3,000 
patients seen regularly at RLANRC with some degree of paralysis ).  The accrual goal is two.  Only one site, 
RLANRC , will be involved in re cruiting subjects for this study.  
 
13.3 Study Design  
 
This study is designed as a longitudinal feasibility study in which two subjects will each receive the NPS and each 
will serve as his or her own control.  Each subject may withdraw from the study independent ly of the other before 
reaching the end of the study period at his or her request, physician request, or due to an adverse event.  If an 
adverse event occurs which is determined to be caused by a defect of the device, which is determined to place 
undue ris k on the subjects of the study, the study will end early and all enrolled subjects will be withdrawn from 
the study.  
 
No stratification factors will be incorporated into this study.  Both study subjects will be recruited from the same 
population of paralyz ed patients with history of high cervical spinal lesion (C4 and above), and other inclusion and 
exclusion criteria as outlined in the inclusion criteria (Section 5.0 ). 
 
13.4 Statistical Power of the Study  
 
With only two subjects, the statistical power of this study to support conclusions for the population of paralyzed 
patients at large is weak.  This study is not intended to bring statistical power to bear on making conclusions about 
the absolute safety of the device.  This is a pilot study intended to evaluate the basic safety and effectiveness of the 
device.  Given the nature of the device and its early state of development, it is appropriate and necessary to initiate 
a small, longitudinal feasibility study.  Therefore, only two subjects will be recruited into the study.  The study 
outcomes for these subjects will be used to evaluate whether more and larger studies are warranted.  
 
13.5 Power to Address Objectives  
 
The pri mary objective of this study is to evaluate the safety of the NPS.  By implanting the device in two subjects 
and monitoring their health over the course of the study, the primary safety objective will be satisfied.   
 
The secondary objective of this study is to evaluate the effectiveness of the NPS  when controlling virtual or 
physical end effectors .  By monitoring the subjects as they perform study tasks  using the NPS , the primary 
effectiveness objectives of this study will be satisfied.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  41 14.0 Registration Gui deline  
 
14.1 Patient Registration  
 
The subject will be officially registered upon provision of informed consent to the physician.  
 
14.2 Registration Forms and Records  
 
Registration forms include Consent Information and  Inclusion/Exclusion clinical notes (Section 18.4) , and the 
Patient Manual (Section 18.3) .   
 
Two copies of the sign ed and dated patient Informed Consent form with Bill of Rights will be available (an 
original for patient’s medical chart; one copy for the patient; and the other for the PI’s file).  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  42 15.0 Biohazard Containment  
 
There will be no biohazard materials associated  with this clinical study outside of the standard clinical 
environment.  All biohazardous material (e.g., sharps) generated in the clinical environment will be disposed of 
according to the standard practice and methods set forth by the established clinical  protocol.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  43 16.0 Ethical and Regulatory Considerations  
 
All institutional and Federal regulations concerning the Informed Consent form will be fulfilled.  The study will be 
conducted in adherence to ICH Good Clinical Practice.  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  44 17.0 References  
 
1. Hochberg LR, Donoghue JP. Sensors for brain -computer interfaces. IEEE engineering in medicine and biology 
magazine : the quarterly magazine of the Engineering in Medicine & Biology Society. 2006;25(5):32 -8. Epub 
2006/10/06.  
2. Hochberg  LR, Serruya MD, Friehs GM, Mukand JA, Saleh M, Caplan AH, et al. Neuronal ensemble control of 
prosthetic devices by a human with tetraplegia. Nature. 2006;442(7099):164- 71. Epub 2006/07/14.  
3. Kim S, Simeral JD, Hochberg LR, Donoghue JP, Black MJ, editors . Computer cursor control by motor cortical 
signals in humans with tetraplegia. Asian Control Conference, 2009 ASCC 2009 7th; 2009 27- 29 Aug. 2009.  
4. Kim S, Simeral JD, Hochberg LR, Donoghue JP, Friehs GM, Black MJ, editors. Multi -state decoding of point -
and-click control signals from motor cortical activity in a human with tetraplegia. Neural Engineering, 2007 CNE 
'07 3rd International IEEE/EMBS Conference on; 2007 2- 5 May 2007.  
5. Kim SP, Simeral JD, Hochberg LR, Donoghue JP, Black MJ. Neural control of computer cursor velocity by 
decoding motor cortical spiking activity in humans with tetraplegia. Journal of neural engineering. 2008;5(4):455-
76. Epub 2008/11/19.  
6. Kim SP, Simeral JD, Hochberg LR, Donoghue JP, Friehs GM, Black MJ. Point -and-click cursor control with an 
intracortical neural interface system by humans with tetraplegia. IEEE transactions on neural systems and 
rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society. 
2011;19(2):193- 203. Epub 2011/02/0 1. 
7. Simeral JD, Kim SP, Black MJ, Donoghue JP, Hochberg LR. Neural control of cursor trajectory and click by a 
human with tetraplegia 1000 days after implant of an intracortical microelectrode array. Journal of neural 
engineering. 2011;8(2):025027. Epub 2011/03/26.  
8. Truccolo W, Friehs GM, Donoghue JP, Hochberg LR. Primary motor cortex tuning to intended movement 
kinematics in humans with tetraplegia. The Journal of neuroscience : the official journal of the Society for 
Neuroscience. 2008;28(5):1163- 78. Epub 2008/02/01.  
9. Paninski L, Fellows MR, Hatsopoulos NG, Donoghue JP. Spatiotemporal tuning of motor cortical neurons for 
hand position and velocity. Journal of neurophysiology. 2004;91(1):515- 32. Epub 2003/09/19.  
10. Schwartz AB, Taylor DM, Tillery SI.  Extraction algorithms for cortical control of arm prosthetics. Current opinion 
in neurobiology. 2001;11(6):701- 7. Epub 2001/12/13.  
11. Ungerleider LG, Mishkin M. Two cortical visual systems. In: Ingle J, Goodale MA, Mansfield RJW, editors. 
Analysis of vis ual behavior. Cambridge, MA: MIT Press; 1982. p. 549- 86. 
12. Goodale MA, Milner AD. Separate visual pathways for perception and action. Trends in neurosciences. 
1992;15(1):20- 5. Epub 1992/01/01.  
13. Mountcastle VB, Lynch JC, Georgopoulos A, Sakata H, Acuna  C. Posterior parietal association cortex of the 
monkey: command functions for operations within extrapersonal space. Journal of neurophysiology. 
1975;38(4):871- 908. Epub 1975/07/01.  
14. Musallam S, Corneil BD, Greger B, Scherberger H, Andersen RA. Cogniti ve control signals for neural prosthetics. 
Science. 2004;305(5681):258- 62. Epub 2004/07/13.  
15. Andersen RA, Buneo CA. Intentional maps in posterior parietal cortex. Annual review of neuroscience. 
2002;25:189- 220. Epub 2002/06/08.  
16. Gail A, Andersen RA. Neural dynamics in monkey parietal reach region reflect context -specific sensorimotor 
transformations. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
2006;26(37):9376- 84. Epub 2006/09/15.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  45 17. Snyder LH, Batista AP, Ande rsen RA. Intention -related activity in the posterior parietal cortex: a review. Vision 
research. 2000;40(10- 12):1433- 41. Epub 2000/05/02.  
18. Gnadt JW, Andersen RA. Memory related motor planning activity in posterior parietal cortex of macaque. 
Experimenta l brain research Experimentelle Hirnforschung Experimentation cerebrale. 1988;70(1):216- 20. Epub 
1988/01/01.  
19. Snyder LH, Batista AP, Andersen RA. Coding of intention in the posterior parietal cortex. Nature. 
1997;386(6621):167- 70. Epub 1997/03/13.  
20. Sakata H, Taira M, Murata A, Mine S. Neural mechanisms of visual guidance of hand action in the parietal cortex 
of the monkey. Cereb Cortex. 1995;5(5):429- 38. Epub 1995/09/01.  
21. Buneo CA, Jarvis MR, Batista AP, Andersen RA. Direct visuomotor transformatio ns for reaching. Nature. 
2002;416(6881):632- 6. Epub 2002/04/12.  
22. Lacquaniti F, Guigon E, Bianchi L, Ferraina S, Caminiti R. Representing spatial information for limb movement: 
role of area 5 in the monkey. Cereb Cortex. 1995;5(5):391- 409. Epub 1995/09/01.  
23. Sakata H, Takaoka Y, Kawarasaki A, Shibutani H. Somatosensory properties of neurons in the superior parietal 
cortex (area 5) of the rhesus monkey. Brain research. 1973;64:85 -102. Epub 1973/12/21.  
24. Seelke AM, Padberg JJ, Disbrow E, Purnell SM, Recanzone G, Krubitzer L. Topographic Maps within 
Brodmann's Area 5 of Macaque Monkeys. Cereb Cortex. 2011. Epub 2011/10/01.  
25. Cui H, Andersen RA. Posterior parietal cortex encodes autonomously selected motor plans. Neuron. 
2007;56(3):552- 9. Epub 2007/11/09.  
26. Bracewell RM, Mazzoni P, Barash S, Andersen RA. Motor intention activity in the macaque's lateral intraparietal 
area. II. Changes of motor plan. Journal of neurophysiology. 1996;76(3):1457- 64. Epub 1996/09/01.  
27. Snyder LH, Batista AP, Andersen RA. Change in motor plan, without a change in the spatial locus of attention, 
modulates activity in posterior parietal cortex. Journal of neurophysiology. 1998;79(5):2814- 9. Epub 1998/05/20.  
28. Batista AP, Buneo CA, Snyder LH, Andersen RA. Reach plans in eye -centered coordinates. Science. 
1999;285(5425):257- 60. Epub 1999/07/10.  
29. Cui H, Andersen RA. Different representations of potential and selected motor plans by distinct parietal areas. The 
Journal of neuroscience : the official journal of the Society  for Neuroscience. 2011;31(49):18130- 6. Epub 
2011/12/14.  
30. Bremner L, Andersen RA. Reference frames for reaching in parietal area 5d.  2011 Neuroscience Meeting Planner; 
Washington, D.C.: Society for Neuroscience; 2011.  
31. Scherberger H, Jarvis MR, Andersen RA. Cortical local field potential encodes movement intentions in the 
posterior parietal cortex. Neuron. 2005;46(2):347- 54. Epub 2005/04/26.  
32. Pesaran B, Pezaris JS, Sahani M, Mitra PP, Andersen RA. Temporal structure in neuronal activity during wor king 
memory in macaque parietal cortex. Nature neuroscience. 2002;5(8):805 -11. Epub 2002/07/23.  
33. Hwang EJ, Andersen RA. Brain control of movement execution onset using local field potentials in posterior 
parietal cortex. The Journal of neuroscience : th e official journal of the Society for Neuroscience. 
2009;29(45):14363- 70. Epub 2009/11/13.  
34. Andersen RA, Musallam S, Pesaran B. Selecting the signals for a brain -machine interface. Current opinion in 
neurobiology. 2004;14(6):720 -6. Epub 2004/12/08.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  46 35. Hwang EJ, Andersen RA. Spiking and LFP activity in PRR during symbolically instructed reaches. Journal of 
neurophysiology. 2012;107(3):836- 49. Epub 2011/11/11.  
36. Szarowski DH, Andersen MD, Retterer S, Spence AJ, Isaacson M, Craighead HG, et al. Brain res ponses to micro-
machined silicon devices. Brain research. 2003;983(1 -2):23- 35. Epub 2003/08/14.  
37. Cavina -Pratesi C, Monaco S, Fattori P, Galletti C, McAdam TD, Quinlan DJ, et al. Functional magnetic resonance 
imaging reveals the neural substrates of arm transport and grip formation in reach -to-grasp actions in humans. The 
Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30(31):10306 -23. Epub 
2010/08/06.  
38. Prado J, Clavagnier S, Otzenberger H, Scheiber C, Kennedy H, Perenin MT. Two cortical systems for reaching in 
central and peripheral vision. Neuron. 2005;48(5):849- 58. Epub 2005/12/13.  
39. Scheperjans F, Hermann K, Eickhoff SB, Amunts K, Schleicher A, Zilles K. Observer -independent 
cytoarchitectonic mapping of the hum an superior parietal cortex. Cereb Cortex. 2008;18(4):846- 67. Epub 
2007/07/24.  
40. Medendorp WP, Goltz HC, Vilis T, Crawford JD. Gaze -centered updating of visual space in human parietal 
cortex. The Journal of neuroscience : the official journal of the Soci ety for Neuroscience. 2003;23(15):6209- 14. 
Epub 2003/07/18.  
41. Astafiev SV, Shulman GL, Stanley CM, Snyder AZ, Van Essen DC, Corbetta M. Functional organization of 
human intraparietal and frontal cortex for attending, looking, and pointing. The Journal of  neuroscience : the 
official journal of the Society for Neuroscience. 2003;23(11):4689- 99. Epub 2003/06/14.  
42. Simon O, Mangin JF, Cohen L, Le Bihan D, Dehaene S. Topographical layout of hand, eye, calculation, and 
language -related areas in the human pari etal lobe. Neuron. 2002;33(3):475- 87. Epub 2002/02/08.  
43. Grefkes C, Ritzl A, Zilles K, Fink GR. Human medial intraparietal cortex subserves visuomotor coordinate 
transformation. NeuroImage. 2004;23(4):1494- 506. Epub 2004/12/14.  
44. Frey SH, Vinton D, Nor lund R, Grafton ST. Cortical topography of human anterior intraparietal cortex active 
during visually guided grasping. Brain research Cognitive brain research. 2005;23(2 -3):397- 405. Epub 
2005/04/12.  
45. Binkofski F, Dohle C, Posse S, Stephan KM, Hefter H, Seitz RJ, et al. Human anterior intraparietal area subserves 
prehension: a combined lesion and functional MRI activation study. Neurology. 1998;50(5):1253- 9. Epub 
1998/05/22.  
46. Binkofski F, Buccino G, Posse S, Seitz RJ, Rizzolatti G, Freund H. A fronto -parietal circuit for object 
manipulation in man: evidence from an fMRI -study. The European journal of neuroscience. 1999;11(9):3276- 86. 
Epub 1999/10/06.  
47. Culham JC, Danckert SL, DeSouza JF, Gati JS, Menon RS, Goodale MA. Visually guided grasping produces 
fMRI activation in dorsal but not ventral stream brain areas. Experimental brain research Experimentelle 
Hirnforschung Experimentation cerebrale. 2003;153(2):180- 9. Epub 2003/09/10.  
48. Tunik E, Frey SH, Grafton ST. Virtual lesions of the anterior  intraparietal area disrupt goal -dependent on- line 
adjustments of grasp. Nature neuroscience. 2005;8(4):505- 11. Epub 2005/03/22.  
49. Monaco S, Cavina -Pratesi C, Sedda A, Fattori P, Galletti C, Culham JC. Functional magnetic resonance adaptation 
reveals the involvement of the dorsomedial stream in hand orientation for grasping. Journal of neurophysiology. 
2011;106(5):2248- 63. Epub 2011/07/29.  
50. Gallivan JP, McLean DA, Valyear KF, Pettypiece CE, Culham JC. Decoding action intentions from preparatory 
brain a ctivity in human parieto -frontal networks. The Journal of neuroscience : the official journal of the Society 
for Neuroscience. 2011;31(26):9599- 610. Epub 2011/07/01.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  47 51. Connolly JD, Andersen RA, Goodale MA. FMRI evidence for a 'parietal reach region' in t he human brain. 
Experimental brain research Experimentelle Hirnforschung Experimentation cerebrale. 2003;153(2):140 -5. Epub 
2003/09/05.  
52. Polikov VS, Tresco PA, Reichert WM. Response of brain tissue to chronically implanted neural electrodes. 
Journal of neuroscience methods. 2005;148(1):1- 18. Epub 2005/10/04.  
53. Biran R, Martin DC, Tresco PA. Neuronal cell loss accompanies the brain tissue response to chronically implanted 
silicon microelectrode arrays. Experimental neurology. 2005;195(1):115- 26. Epub 20 05/07/28.  
54. McConnell GC, Rees HD, Levey AI, Gutekunst CA, Gross RE, Bellamkonda RV. Implanted neural electrodes 
cause chronic, local inflammation that is correlated with local neurodegeneration. Journal of neural engineering. 
2009;6(5):056003. Epub 2009 /08/25.  
55. Nielsen MS, Bjarkam CR, Sorensen JC, Bojsen -Moller M, Sunde NA, Ostergaard K. Chronic subthalamic high -
frequency deep brain stimulation in Parkinson's disease --a histopathological study. European journal of neurology 
: the official journal of the European Federation of Neurological Societies. 2007;14(2):132 -8. Epub 2007/01/26.  
56. Chestek CA, Gilja V, Nuyujukian P, Foster JD, Fan JM, Kaufman MT, et al. Long -term stability of neural 
prosthetic control signals from silicon cortical arrays in rhes us macaque motor cortex. Journal of neural 
engineering. 2011;8(4):045005. Epub 2011/07/22.  
57. Mulliken GH, Musallam S, Andersen RA. Decoding trajectories from posterior parietal cortex ensembles. The 
Journal of neuroscience : the official journal of the S ociety for Neuroscience. 2008;28(48):12913- 26. Epub 
2008/11/28.  
58. Mulliken GH, Musallam S, Andersen RA. Forward estimation of movement state in posterior parietal cortex. 
Proceedings of the National Academy of Sciences of the United States of America. 20 08;105(24):8170- 7. Epub 
2008/05/24.  
59. Hauschild M, Mulliken GH, Loeb GE, Andersen RA. Decoding instantaneous hand position from posterior 
parietal cortex in a natural task.  2008 Neuroscience Meeting Planner; Washington, D.C.: Society for 
Neuroscience; 2 008. 
60. Baldauf D, Cui H, Andersen RA. The posterior parietal cortex encodes in parallel both goals for double- reach 
sequences. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2008;28(40):10081-
9. Epub 2008/10/03.  
61. Chang SW, Dickinson AR, Snyder LH. Limb -specific representation for reaching in the posterior parietal cortex. 
The Journal of neuroscience : the official journal of the Society for Neuroscience. 2008;28(24):6128- 40. Epub 
2008/06/14.  
62. Chang SW, Snyder LH.  The Representations of Reach Endpoints in Posterior Parietal Cortex Depend On Which 
Hand Does the Reaching. Journal of neurophysiology. 2012. Epub 2012/02/03.  
63. Baumann MA, Fluet MC, Scherberger H. Context -specific grasp movement representation in the m acaque anterior 
intraparietal area. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
2009;29(20):6436- 48. Epub 2009/05/22.  
64. Townsend BR, Subasi E, Scherberger H. Grasp movement decoding from premotor and parietal corte x. The 
Journal of neuroscience : the official journal of the Society for Neuroscience. 2011;31(40):14386 -98. Epub 
2011/10/07.  
65. Stetson CA, Andersen RA. Asymmetry of cross -cortical spike -LFP coherence.  2011 Neuroscience Meeting 
Planner; Washington, D.C. : Society for Neuroscience; 2011.  
66. Andersen RA, Cui H. Intention, action planning, and decision making in parietal -frontal circuits. Neuron. 
2009;63(5):568- 83. Epub 2009/09/17.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  48 67. Andersen RA, Burdick JW, Musallam S, Pesaran B, Cham JG. Cognitive neura l prosthetics. Trends in cognitive 
sciences. 2004;8(11):486- 93. Epub 2004/10/20.  
68. Dun CA, Faber HT, de Wolf MJ, Mylanus EA, Cremers CW, Hol MK. Assessment of more than 1,000 implanted 
percutaneous bone conduction devices: skin reactions and implant surv ival. Otology & neurotology : official 
publication of the American Otological Society, American Neurotology Society [and] European Academy of 
Otology and Neurotology. 2012;33(2):192- 8. Epub 2012/01/17.  
69. Hobson JC, Roper AJ, Andrew R, Rothera MP, Hill P,  Green KM. Complications of bone -anchored hearing aid 
implantation. The Journal of laryngology and otology. 2010;124(2):132- 6. Epub 2009/12/09.  
70. House JW, Kutz JW, Jr. Bone -anchored hearing aids: incidence and management of postoperative complications. 
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society 
[and] European Academy of Otology and Neurotology. 2007;28(2):213- 7. Epub 2007/01/27.  
71. Reyes RA, Tjellstrom A, Granstrom G. Evaluation of impla nt losses and skin reactions around extraoral bone -
anchored implants: A 0 - to 8-year follow -up. Otolaryngology --head and neck surgery : official journal of 
American Academy of Otolaryngology -Head and Neck Surgery. 2000;122(2):272- 6. Epub 2000/02/01.  
72. Dashti SR, Baharvahdat H, Spetzler RF, Sauvageau E, Chang SW, Stiefel MF, et al. Operative intracranial 
infection following craniotomy. Neurosurgical focus. 2008;24(6):E10. Epub 2008/06/04.  
73. Erman T, Demirhindi H, Gocer AI, Tuna M, Ildan F, Boyar B. Risk factors for surgical site infections in 
neurosurgery patients with antibiotic prophylaxis. Surgical neurology. 2005;63(2):107- 12; discussion 12- 3. Epub 
2005/02/01.  
74. Lietard C, Thebaud V, Besson G, Lejeune B. Risk factors for neurosurgical site infection s: an 18 -month 
prospective survey. Journal of neurosurgery. 2008;109(4):729- 34. Epub 2008/10/02.  
75. McClelland S, 3rd, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 
2111 neurosurgical procedures. Clinical inf ectious diseases : an official publication of the Infectious Diseases 
Society of America. 2007;45(1):55- 9. Epub 2007/06/08.  
76. McClelland S, 3rd. Postoperative intracranial neurosurgery infection rates in North America versus Europe: a 
systematic analysis . American journal of infection control. 2008;36(8):570- 3. Epub 2008/10/18.  
77. Mu Y, Edwards JR, Horan TC, Berrios -Torres SI, Fridkin SK. Improving risk -adjusted measures of surgical site 
infection for the national healthcare safety network. Infection con trol and hospital epidemiology : the official 
journal of the Society of Hospital Epidemiologists of America. 2011;32(10):970- 86. Epub 2011/09/21.  
78. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System 
Report, data summary from January 1992 through June 2004, issued October 2004. American journal of infection 
control. 2004;32(8):470- 85. Epub 2004/12/02.  
79. Umemura A, Oka Y, Yamamoto K, Okita K, Matsukawa N, Yamada K. Complications of subthalamic nucleus 
stimulation in Parkinson's disease. Neurologia medico -chirurgica. 2011;51(11):749- 55. Epub 2011/11/30.  
80. Fenoy AJ, Simpson RK, Jr. Management of device -related wound complications in deep brain stimulation surgery. 
Journal of neurosurgery. 2012. Epub 201 2/03/13.  
81. Gorgulho A, De Salles AA, Frighetto L, Behnke E. Incidence of hemorrhage associated with electrophysiological 
studies performed using macroelectrodes and microelectrodes in functional neurosurgery. Journal of neurosurgery. 
2005;102(5):888- 96. Epub 2005/06/02.  
82. Kleiner -Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus deep brain 
stimulation: summary and meta -analysis of outcomes. Movement disorders : official journal of the Movement 
Disorder Society. 2006;21 Suppl 14:S290- 304. Epub 2006/08/08.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  49 83. Constantoyannis C, Berk C, Honey CR, Mendez I, Brownstone RM. Reducing hardware -related complications of 
deep brain stimulation. The Canadian journal of neurological sciences Le journal canadien des sciences 
neurologiques. 2005;32(2):194- 200. Epub 2005/07/16.  
84. Lyons KE, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of subthalamic stimulation: 
a series of 160 procedures. Neurology. 2004;63(4):612- 6. Epub 2004/08/25.  
85. Sansur CA, Frysinger RC, Pouratian N, Fu KM, Bittl M, Oskouian RJ, et al. Incidence of symptomatic 
hemorrhage after stereotactic electrode placement. Journal of neurosurgery. 2007;107(5):998- 1003. Epub 
2007/11/06.  
86. Shellock FG, Crues JV. MR procedures: biologic effec ts, safety, and patient care. Radiology. 2004;232(3):635- 52. 
Epub 2004/07/31.  
87. Hamer HM, Morris HH, Mascha EJ, Karafa MT, Bingaman WE, Bej MD, et al. Complications of invasive video -
EEG monitoring with subdural grid electrodes. Neurology. 2002;58(1):97- 103. Epub 2002/01/10.  
88. Tanriverdi T, Ajlan A, Poulin N, Olivier A. Morbidity in epilepsy surgery: an experience based on 2449 epilepsy 
surgery procedures from a single institution. Journal of neurosurgery. 2009;110(6):1111- 23. Epub 2009/02/10.  
89. Wong CH, Birkett J, Byth K, Dexter M, Somerville E, Gill D, et al. Risk factors for complications during 
intracranial electrode recording in presurgical evaluation of drug resistant partial epilepsy. Acta neurochirurgica. 
2009;151(1):37- 50. Epub 2009/01/09.  
90. Morace R, Di Gennaro G, Picardi A, Quarato PP, Sparano A, Mascia A, et al. Surgery after intracranial 
investigation with subdural electrodes in patients with drug -resistant focal epilepsy: outcome and complications. 
Neurosurgical review. 2012. Epub 2012/03/22.  
91. Binder DK, Podlogar M, Clusmann H, Bien C, Urbach H, Schramm J, et al. Surgical treatment of parietal lobe 
epilepsy. Journal of neurosurgery. 2009;110(6):1170- 8. Epub 2009/02/10.  
92. Turner JN, Shain W, Szarowski DH, Andersen M, Martins S, Isaacs on M, et al. Cerebral astrocyte response to 
micromachined silicon implants. Experimental neurology. 1999;156(1):33- 49. Epub 1999/04/08.  
93. Baker J, Bishop W, Kellis S, Levy T, House P, Greger B. Multi -scale recordings for neuroprosthetic control of 
finger  movements. Conference proceedings :  Annual International Conference of the IEEE Engineering in 
Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Conference. 2009;2009:4573-
7. Epub 2009/12/08.  
94. Batista AP, Yu BM, Santhanam G , Ryu SI, Afshar A, Shenoy KV. Cortical neural prosthesis performance 
improves when eye position is monitored. IEEE transactions on neural systems and rehabilitation engineering : a 
publication of the IEEE Engineering in Medicine and Biology Society. 2008; 16(1):24- 31. Epub 2008/02/29.  
95. Dickey AS, Suminski A, Amit Y, Hatsopoulos NG. Single -unit stability using chronically implanted 
multielectrode arrays. Journal of neurophysiology. 2009;102(2):1331- 9. Epub 2009/06/19.  
96. Egan J, Baker J, House P, Greger B. Detection and classification of multiple finger movements using a chronically 
implanted Utah Electrode Array. Conference proceedings :  Annual International Conference of the IEEE 
Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Conference. 
2011;2011:7320- 3. Epub 2012/01/19.  
97. Fraser GW, Chase SM, Whitford A, Schwartz AB. Control of a brain -computer interface without spike sorting. 
Journal of neural engineering. 2009;6(5):055004. Epub 2009/09/02.  
98. Manyakov  NV, Van Hulle MM. Synchronization in monkey visual cortex analyzed with an information -theoretic 
measure. Chaos. 2008;18(3):037130. Epub 2008/12/03.  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  50 99. Ryu SI, Shenoy KV. Human cortical prostheses: lost in translation? Neurosurgical focus. 2009;27(1):E5.  Epub 
2009/07/03.  
100. Suner S, Fellows MR, Vargas -Irwin C, Nakata GK, Donoghue JP. Reliability of signals from a chronically 
implanted, silicon -based electrode array in non -human primate primary motor cortex. IEEE transactions on neural 
systems and rehabi litation engineering : a publication of the IEEE Engineering in Medicine and Biology Society. 
2005;13(4):524- 41. Epub 2006/01/24.  
101. Torab K, Davis TS, Warren DJ, House PA, Normann RA, Greger B. Multiple factors may influence the 
performance of a visual prosthesis based on intracortical microstimulation: nonhuman primate behavioural 
experimentation. Journal of neural engineering. 2011;8(3):035001. Epub 2011/05/20.  
102. Batista AP, Andersen RA. The parietal reach region codes the next planned movement in a sequential reach task. 
Journal of neurophysiology. 2001;85(2):539- 44. Epub 2001/02/13.  
103. Quiroga RQ, Snyder LH, Batista AP, Cui H, Andersen RA. Movement intention is better predicted than attention 
in the posterior parietal cortex. The Journal of neuro science : the official journal of the Society for Neuroscience. 
2006;26(13):3615- 20. Epub 2006/03/31.  
104. Scherberger H, Andersen RA. Target selection signals for arm reaching in the posterior parietal cortex. The 
Journal of neuroscience : the official jo urnal of the Society for Neuroscience. 2007;27(8):2001- 12. Epub 
2007/02/23.  
105. Shenoy KV, Meeker D, Cao S, Kureshi SA, Pesaran B, Buneo CA, et al. Neural prosthetic control signals from 
plan activity. Neuroreport. 2003;14(4):591- 6. Epub 2003/03/27.  
106. Anderson KD. Targeting recovery: priorities of the spinal cord -injured population. Journal of neurotrauma. 
2004;21(10):1371- 83. Epub 2005/01/28.  
107. Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, et al. Electrical stimulation of the anterior nuc leus of 
thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51(5):899- 908. Epub 2010/03/25.  
108. Morrell MJ, Group RNSSiES. Responsive cortical stimulation for the treatment of medically intractable partial 
epilepsy. Neurology. 2011;77(13):1295- 304. Epub 2011/09/16.  
109. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and 
research. International journal of rehabilitation research Internationale Zeitschrift fur Rehabilitationsforschung 
Revue internationale de recherches de readaptation. 1981;4(4):483- 92. Epub 1981/01/01.  
110. Law M, Baptiste S, McColl M, Opzoomer A, Polatajko H, Pollo ck N. The Canadian occupational performance 
measure: an outcome measure for occupational therapy. Canadian journal of occupational therapy Revue 
canadienne d'ergotherapie. 1990;57(2):82- 7. Epub 1990/04/01.  
111. Diener E, Emmons RA, Larsen RJ, Griffin S. Th e Satisfaction With Life Scale. Journal of personality assessment. 
1985;49(1):71- 5. Epub 1985/02/01.  
112. Kemp BJ, Bateham AL, Mulroy SJ, Thompson L, Adkins RH, Kahan JS. Effects of reduction in shoulder pain on 
quality of life and community activities amo ng people living long- term with SCI paraplegia: a randomized control 
trial. The journal of spinal cord medicine. 2011;34(3):278- 84. Epub 2011/07/16.  
 
 
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  51 18.0 Appendix 
 
The appendices include the following items:  
 
• Clinical Calendar  (Section 18.1)  
• Informed Consent Document ( 18.2)  
• NPS Patient Manual  (Section 18.3)  
• Clinical Notes  (Section 18.4)  
• Rey Auditory Verbal Learning Test Normat ive Data  (Section 18.5)  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  52 18.1 Clinical Calendar  
 
  Table 18- 1 Calendar of Study Procedures and Activities  
 
Procedure  Eligibility  Baseline  Implant  Healing  
Period Study  
Period Explan t Follow -up 
(N/A)  (N/A)  Week 0 Weeks 0-2 Weeks 3 -52 Week 52 Week 53+ 
Protocol Activities         
Rey Auditory Verbal Learning Test  X       
Symptom Checklist -90-Revised 
Test X       
Cognitive Abilities Screening 
Instrument  X       
Vital Sign Measurements  X X X X X2 X X3 
Administer Quality -of-Life Survey   X   X2  X 
Complete Medical History   X      
Complete Physical Examination   X      
Complete Neurological 
Examination   X  X X2  X3 
Electrocardiogram (EKG)   X    X  
Chest X -Ray  X      
Rapid Plasma Reagin (RPR) Test   X      
Complete Blood Count (CBC)   X X   X  
Complete Metabolic Panel (CMP)   X X   X  
Urine Pregnancy Test1  X X   X  
Urinalysis (UA)    X   X  
Prothrombin Time (PT)/  
Partial Thromboplastin Time (PTT) 
Test   X   X  
General Anesthesia    X   X  
Brain MRI    X    X 
Pre-operative antibiotics 
(Vancomycin 1 gram IV)    X   X  
Post-operative anti -seizure (Keppra 
500 mg PO q12 hours for two 
weeks)    X   X  
Post-operative antibiotic ( NAME? 
QUANT?  24 hours)    X   X  
Post-operative CT scan     X  X  
Task 1: Fixed Targets      X4   
Task 2: Continuous Positioning      X4   
 
1 For women of childbearing age.  
2 To occur once per month during the indicated study phase . 
3 To occur at 1 -week, 6 -week, and 3 -month intervals after surgery  
4 To occur 3- 5 times per week for the indicated study phase . 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  53   Table 18- 2 Calendar of Source Documents  
 
Procedure  Eligibility  Baseline  Implant  Healing 
Period  Study 
Period  Explant  Follow -
up 
(variable)  (variable)  Week 0  Weeks 0 -
2 Weeks 2 -52 Week 52  Weeks 
53+ 
Source Document Schedule         
Adverse Event Clinical Note   When Applicable  
Action Research Arm Test (ARAT) 
Clinical Note      X1   
Canadian Occupational 
Performance Measure (COPM) 
Clinical Note      X2   
Conclusion/Withdrawal Clinical 
Note       X3  
Consent Information Clinical Note  X4       
Inclusion/Exclusion Clinical Note  X       
Initial Office Appointment Clinical 
Note  X       
Office Appointment Clinical Note   X X X X X X 
Quality -of-life Index (QOLI)   X   X2  X 
Study Session Clinical Note      X5   
Surgical Procedure Clinical Note    X   X  
Hospital Discharge Summary 
Dictation    X   X  
Implant Procedure Summary 
Dictation    X     
 
1 To occur at 10 week intervals beginning the week after healing.  
2 To occur once per month during the indicated study phase . 
3 Expected to occur when indicated, but may occur at any time during the course of the study due to patient election, adverse 
event, etc.  
4 To occur prior to any tests, procedures, or study activities.  
5 To occur 3- 5 times per week for the indicated study phase . 
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  54 18.2 Informed Consent Document  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  55 18.3 NPS Patient Manual  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  56 18.4 Clinical Notes  
 
The following clinical notes are included in this section:  
 
• Adverse Event  
• Action Research Arm Test (ARAT)  
• Canadian Occupational  Performance Measure (COPM)  
• Conclusion/Withdrawal  
• Consent Information 
• Inclusion/Exclusion  
• Initial Office Appointment  
• Office Appointment  
• Quality of Life Index (QOLI)  
• Study Session  
• Surgical Procedure  
 
  
Doc: Proform   
 
Version date: 04/15/12  
Confidential  57 18.5 Rey Auditory Verbal Learning Test Normative Data  
 
Tables 18 -3 and 18- 4 list the exclusion thresholds by age for females and males (respectively).  Subjects who score 
lower than the age -appropriate threshold in any of the A5, A6, or A7 components of the RAVLT will be excluded 
from the study.  
 
 
Table 18 -3.  RAVLT Exclusion Thresholds by Age: Females  
 Age Groups  
 16-19 20-29 30-39 40-49 50-59 60-69 70+ 
Trial A5  11.8 11.4 11.4 10.9 9.5 10.3 8.9 
Trial A6  9.6 9.1 10.2 8.7 7.1 8.2 6.0 
Trial A7  8.9 10.0 9.7 8.8 7.5 8.0 6.2 
 
 
 
Table 18 -4.  RAVLT Exclusion Thresholds by Age: Males  
 Age Groups  
 16-19 20-29 30-39 40-49 50-59 60-69 70+ 
Trial A5  11.2 11.0 8.8 8.9 9.2 6.9 5.7 
Trial A6  9.6 9.4 7.4 7.2 6.7 4.4 4.7 
Trial A7  9.6 9.2 8.1 7.8 7.4 3.3 3.0 
 
 